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Structure of the thesis 
 
To fully represent the result, the cumulative form of the Habilitation Thesis was selected. The 
description of the present work is organized as follows. The first chapter described the various 
types of stem cells, the key areas of stem cell based cardiac therapy for cardiac applications 
and gene enhancement of stem cell for cardiac therapy.  
Chapter 2 concerns the two polyplex gene vectors for cell manipulation and describes the 
feasibility study of usage of the nonviral gene carrier. The ability of poly ethyleneimine (PEI) 
to mediate in vivo gene delivery to the Central Nervous System (CNS) by retrograde transport 
was explored after peripheral intramuscular injection. The development and evaluation of the 
cell-type specific transfecting peptide, is described also in Chapter 2.  
Chapter 3 describes the latest development of stem cells and their cardiac benefit. In the earlier 
part of this chapter, organ-specific homing pattern of human mononuclear cord blood (hUCB) 
cells is investigated in a non-obese diabetic severe combined immunodeficiency (NOD/scid) 
mouse model. We proved that hUCB cells could specifically migrate to the heart after 
myocardial infarction, participate in tissue remodelling, and possibly facilitate regeneration 
processes after intravanous application. Furthermore, the myocardial regeneration potential of 
CD(cluster of differentiation) 133+ cells from bone marrow and cord blood was compared side 
by side in a NOD/scid mouse model of left ventricular cryoinjury. The functional and 
histologic consequence following direct intramyocardial delivery of human CD133+ cells has 
been determined. 
The low cellular survival rate after stem cell transplantation into an infarcted heart within the 
first few days engenders only marginal functional improvement. Thus, in order to improve the 
efficacy of cell therapy it is necessary to reinforce stem cells against the arduous 
microenvironment incurred from ischemia, inflammatory response and pro-apoptotic factors. 
In charpter 4 we attempt to geneticly modify mesenchymal stem cells (MSCs) ex vivo with 
prosurvival gene bcl-2 (B-cell lymphoma 2), by nonviral vector in order to enhance their 
resistance to ischemic conditions from acute myocardial infarction after transplantation into 
the heart. The genetic modification of stem cells with Bcl-2 was found to armour stem cells 
settling into a deteriorative ischemic microenvironment, improve stem cell viability in the 
early post-transplanted period and thereby enhancing cardiac functional recovery after acute 
myocardial infarction.  
Finally, conclusions drawn from the entire body of work are given in Chapter 5. The thesis 
was then followed by selected publications which contain the experimental data, the 
substantial results as well as the detailed discussion of the respective results. 
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Chapter 1 Introduction   
 
LITERATURE REVIEW: STEM CELL AND CARDIAC REGENERATION  
Cardiovascular disease (CVD), which includes hypertension, coronary heart disease (CHD), 
stroke, and congestive heart failure (CHF), has ranked as the number one cause of death in 
Europe with over 2 million people dying from CVD every year. Given the aging of the 
population and the relatively dramatic recent increases in the prevalence of cardiovascular risk 
factors such as obesity and type 2 diabetes, CVD will continue to be a significant health 
problem well into the 21st century. However, improvements in the acute treatment of heart 
attacks and an increasing arsenal of drugs have facilitated survival. Still there is an unmet need 
for therapies to regenerate or repair damaged cardiac tissue.  
 
Cardiac ischemia with shortage of oxygen leads to myocardial damage and cardiomyocyte 
loss. The cardiomyocyte (cardiac muscle cell) loss initiates a cascade of detrimental events, 
including immune response, formation of a non-contractile scar, ventricular wall thinning, and 
volume overload. The endogenous repair mechanisms, including the proliferation and stem cell 
recruitment from bone marrow and heart tissue are not sufficient to repair the damaged tissue. 
Current pharmacologic interventions for heart disease are not able to entirely restore the 
damaged cardiomyocytes.  
 
It has been shown that the heart has the potential for regeneration. Clinical studies have shown 
that intracoronary or intracardiac transplantation of bone marrow stem cells to patients with 
chronic or acute ischemic heart diseases significantly improves the function and regional 
myocardial perfusion of the left ventricle [1-3],  but the effect on heart function and the 
regeneration of heart muscle has been very limited [4]. Therefore, there is a great need for 
further improvement of stem cell property under the ischemic condition, which will brings 
stem cell therapies for heart disease one step closer in the daily clinic. 
1.1 Stem cells 
Stem cells are cells that can differentiate into different kind of cells each exhibiting different 
characteristics such as skin, bone, liver, heart and nerve cells etc. Stem cells have two very 
important properties that distinguish them from other types of cells. First, they are 
unspecialized cells that renew themselves for long periods through cell division. The second is 
that under certain physiologic or experimental conditions, they could be differentiated into 
cells with special functions such as the cardiomyocyte or the insulin-producing cells of the 
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pancreas There are two kinds of stem cells: embryonic stem cell and adult stem cells. Adult 
stem cell could divide into hematopoietic stem cell (HSC) and MSCs. The HSC with an 
extensive capacity of self-renewal is responsible for the production of >95% of the body's 
blood cells [5]. In addition to their self-renewal and multipotent capacity, it has been 
demonstrated primitive HSC with a high "homing to niche" capacity has a high-marrow 
seeding efficiency. HSCs are marked in humans, by c-kit (CD117), thy-1(CD90), and CD34. 
Among these markers, CD34 has been generally used as a convenient positive selection 
marker for HSC. Consequently, CD133 is being newly discovered as an alternative new 
marker to CD34 antigen [6]. The CD133 antigen is a 120-kDa 5-transmembrane domain 
glycoprotein that is expressed in immature hematopoietic stem and progenitor cells [7][8]. In 
addition, several studies indicate that CD133 also serves as a marker for stem and progenitor 
cells with non-hematopoietic, pluripotent differentiation capacity, in particular the subset of 
CD133+ cells that is CD34– [9][10] which is highly expressed on immature stem cells but 
whose expression is lost during the differentiation to mature endothelial cells. CD133+ cell 
products may also contain mesenchymal stem cell-type cells, which have been designated as 
multipotent adult progenitor cells (MAPC) and might possess a particularly broad 
differentiation capacity [11]. The most robust line of evidence, however, indicates that 
CD133+ cells possess the characteristics of endothelial progenitor cells, which can readily be 
differentiated into endothelial cells in vitro and induce or at least participate in 
neoangiogenêsis processes in vivo [12-23]. For those reasons, CD133+ cells were among the 
first cell types to be used in clinical trials of cell therapy for myocardial regeneration, and they 
find increasingly wide-spread application [24-29]. 
MSCs can be isolated from bone marrow and many other sources [30] and can easily be 
expanded in an in vitro cell culture without losing their stem cell properties [31]. Because of 
the ease of the method of their purification and multipotent nature, they have been extensively 
studied in both experimental and clinical settings. In both in vivo and in vitro assays bone 
marrow MSCs appear able to change their fate. 5-bromo-2-deoxyuridine (BrdU) labeled 
marrow MSCs were reported to differentiate into cardiomyocytes after transplantation into the 
myocardium. Red fluorescent protein (DsRed) or GFP (green fluorescent protein) transfected 
human marrow MSCs was injected intraperitoneally into sheep fetuses in utero. It is showed 
that the human cells engrafted in the heart at a late stage of fetal development and 
differentiated into Purkinje fibers in the heart. Treatment of mouse MSCs with 5-azacytidine in 
vitro induced them to differentiate as skeletal muscle cells. Cells of two MSCs lines could 
differentiate as beating cells with a contractile protein profile of fetal ventricular 
cardiomyocytes, either spontaneously after long-term culture or after 5-azacytidine treatment 
[9]. Both these cell, however, expressed the cardiac-specific transcription factor Nkx2.5, which 
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would predispose them toward cardiomyocyte differentiation. There is no universal surface 
marker for the identification of mesenchymal stem cells.  
They are devoid of typical HSC markers such as CD34, and CD45 and express on their surface 
CD44, CD90, CD105, CD106, and CD166 [32]. In addition, they express T cell receptors or 
their components that maintain them readiness stage to enter various pathways of 
differentiation upon induction [33]. It has been shown that CD34– nonhematopoietic bone 
marrow mesenchymal stem cells can differentiate into cardiomyocytes. The heterogeneous 
mononuclear fraction of the bone marrow is the most promising and extensively studied stem 
cell population for cellular cardiomyoplasty [34-36]. Besides, CD117 and Sca-1+ cells have 
also been focused to assess their cardiomyogenic potential [37][38]. 
Bone marrow has long been regarded as the good source of adult stem cells. Recently, stem 
cells have been found in specific tissue such as in the cardiac tissue of the heart, hippocampus 
of the brain, and olfactory bulb. It is generally believed that the embryonic stem cells have the 
most potential to derive into all kinds of cells. Going down the differentiation path from the 
embryonic stem cells are bone marrow stem cells, tissue-specific stem cells, lineage -specific 
precursor cells, and then terminally differentiated specific cells. Stem cells have the tendency 
to be maintained in culture for long period of time, with the capacity for expansion into large 
cell numbers for therapeutic purposes. However, the control of the differentiation path 
becomes more difficult the further upstream is the stem cell. Therefore, embryonic stem cells 
have been the most difficult to produce a pure population of cells for therapeutic applications. 
On the other hand, precursor cells can be induced to become the desired terminally 
differentiated cells in one step induction. These cells normally have less capacity for cell 
expansion. Also, it has been difficult to isolate such precursor cells (e.g. hippocampal neurons 
from the brain) from the patients. Therefore, it has been appealing to have the stem cells that 
can be taken from relatively abundant source such as the bone marrow, cord blood, 
periosteum, adipose tissues and induce them to differentiate into specific types of cells under 
suitable environment and conditions. Adult stem cells taken from tissue biopsy, fat tissue as 
the leftover of cosmetic surgery or from cadaver has been explored as the abundant source of 
adult stem cells as well. Some examples of the adult stem cells are hematopoietic stem cells 
that produce all types of blood cells, skin epithelium and epithelium of the small intestine, 
neural stem cells, and mesenchymal stem cells that can differentiate into cells of the 
musculoskeletal system. 
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1.2 Stem cell cardiac therapy 
Stem cell therapy [39] is quickly emerging as an alternative strategy in cardiovascular 
therapeutics. Proof-of-concept animal studies and phase І clinical trials have already shown the 
safety and feasibility of this approach. The preclinical and clinical studies with unmodified 
autologous or allogenic stem cells principally have demonstrated their potential for repair of 
the injured myocardium. However, there are some fundamental issues that need to be resolved 
to streamline research in this area. The ongoing debate on the role of stem cells cardiac therapy 
has pointed at controversy of underlying mechanisms, optimal cell preparation and functional 
integration as well as need for continuous scrutiny of the adverse effects of the therapy 
(immunogenicity, arrhythmogenesis, and tumorigenicity). 
Cardiac benefit of stem cell transplantation has been vastly reported in vitro and in 
vivo[40][41] However, the exact mechanism of stem cell contributed functional improvement, 
its ability of adult stem cells to transdifferentiate into cardiomyocytes and integrate into the 
host tissue is still in the debate. The achieved cardiomyocyte phenotype was mostly 
demonstrated by the positive expression of various transcription factors. However, the exact 
function of these genes and their activation involved in cardiomyogenic differentiation remains 
a mystery. Many different approaches have been employed to induce cardiogenesis. Coculture 
of bone marrow stem cells with cardiomyocytes has been shown to preprogram these cells to 
adopt a cardiac phenotype. It has been shown that cell-to-cell contact during coculture of bone 
marrow cells with cardiomyocytes is imperative to trigger their cardiomyogenic transformation 
[42].  Several studies have shown that preconditioning in culture using growth factors and 
molecules/hormones results in enhanced therapeutic activity of target stem cells in vivo. The 
activity of these stimuli may enhance survival/proliferation, differentiation/stemness or 
engraftment ability of progenitor cells. For example, the treatment of endothelial progenitor 
cells (EPCs) with statins [43] led to an enhancement of proliferation/survival via 
phosphoinositide 3-kinase (PI3K) signalling while their pretreatment with SDF-1 (stromal cell-
derived factor-1) determined an increase in their engraftment ability in ischemic tissues [44]. 
The use of transcriptionally active drugs such as histone deacetylase or 5-azacytidine has been 
further reported to enhance self renewal of the stem cells populations [45] and to promote 
cardiac differentiation of human bone marrow derived MSC [46]. It has been hypothesized that 
preconditioning of adult stem cell to adopt a cardiomyogenic differentiation before their 
transplantation may have better chances of their transdifferentiation into cardiomyocytes than 
transplantation of unmodified stem cells. The heart function of the 5-Aza-treated bone marrow 
cell transplanted group was better than that of other groups. The injured heart is a more 
efficient inducer of bone marrow cells differentiation into cardiomyocytes (64). The signals 
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originating from the cytokine-rich microenvironment of the injured myocardium and the direct 
cell-cell interaction between donor bone marrow cells and host cardiomyocytes may triggered 
their local protective response such as myogenic differentiation. It has been observed that the 
majority of endothelial cells injected into infarcted mice differentiated into myosin-positive 
cells with a cardiomyocytes-like morphology, whereas only a very few of them differentiated 
into cardiomyocytes after injection into the normal mice heart [47]. It also has been 
demonstrated that endothelial progenitor cells were mobilized into the peripheral blood and 
contributed to neovascularization in the heart during an acute infarction event in humans [48]. 
The angiogenic potential of bone marrow stem cells posttransplantation may be enhanced by 
subjecting the cells to ischemic stress before transplantation [49]. These studies suggested that 
the infarcted heart released into the peripheral blood, which may have trigger stem cell to 
differentiate into specific cell lineages. Taken together, these data suggest that the injured heart 
might have a greater contribution to the milieu-dependent cardiomyocyte differentiation of 
bone marrow cells. However, the information on the signaling molecules and responding 
molecular mechanisms that recruit bone marrow cells to the injured heart and 
transdifferentiation into cardiomyocytes is still unclear. Myocardial infarction can mobilize 
bone marrow cells and recruit them to injured myocardium where they get stimulated for 
transformation into new cardiomyocytes.  
1.3 Gene enhancement of stem cell for cardiac therapy 
1.3.1 Non-viral biocompatible vector for gene modification 
To deliver and express foreign genes in somatic cells in vivo has been a long sought-after goal 
of biological scientists. Gene transfer into postmitotic somatic cells would enable a direct 
analysis of the function and therapeutic effect of a specific protein in an intact organism. In 
view of this, the development of genetic intervention technology has attracted great interest not 
only as a means to resolve fundamental biology questions, but also as a critical step towards 
somatic gene therapy of genetic diseases. Indeed, the application of gene transfer is not limited 
to correcting genetic disorders, but can also be used to augment existing functions or provide 
new ones to cells for therapeutic purposes. 
 
Successful delivery and expression of a therapeutic gene requires efficient and safe vectors that 
carry the gene into the cell nucleus. Vectors may be classified into two categories in terms of 
materials: viral and non-viral vector [50-53]. Viruses have evolved very efficient mechanisms 
to introduce their genetic material into host cells; therefore, they have been the obvious starting 
point to deveop vectors in many gene therapy protocols. However, viral vectors have 
significant disadvantages over nonviral vectors. Even safer, replication-defective viruses may 
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stimulate an immune response that can render repeat administration ineffective. Virus particles 
are also limited as to the sizes of the genes they can accomodate. The viral vector with higher 
transfection efficiency is suffered from high cytotoxicity and strong immunoresponse of virus 
itself. In addition, the cell transfected by virus vector may have mutagenesis. All of the 
remaining drawbacks limit the clinical application of viral system. In addition, nonviral vectors 
are typically easier and less expensive to manufacture. The plasmid DNA used in nonviral 
systems can be conveniently produced in bacteria such as E. coli, whereas packaging of genes 
into viral vectors in a complex procedure. The same production facilities can be used to 
manufacture various plasmids incorporating different genes. Nonviral gene delivery 
technologies include the use of naked DNA, cationic lipids formulated into liposomes and 
complexed with DNA (lipoplexes), cationic polymers complexed with DNA (polyplexes), a 
combination thereof, and DNA-carrying peptides or proteins. The non-viral vector, such as 
naked plasmid DNA and plasmid DNA complexed with cationized carriers, is rather safe and 
has no limitation in the molecular size of DNA applied. Various nonviral vectors have been 
designed and developed, and some of them are in clinical trials. However, nonviral vectors 
encounter many hurdles that result in diminished gene transfer in target cells. The main 
disadvantages of nonviral vectors are formulation inactivation and instability in blood, 
relatively low transfection efficiency, and poor targeting. Cationic vectors sometimes bind 
with serum proteins and blood cells when entering into blood circulation, which results in 
dramatical changes in their physicochemical characters. To reach target cells, nonviral vectors 
should pass through the capillaries, avoid recognition by mononuclear phagocytes, emerge 
from the blood vessels to the interstitium, and bind to the surface of the target cells. They then 
need to be internalized, escape from endosomes, and then find a way to the nucleus, avoiding 
degradation by cytoplasmic enzymes. Successful clinical applications of nonviral vectors will 
require a better understanding of the barriers in gene transfer and development of vectors that 
can overcome these barriers. In addition to these delivery barriers, an ideal nonviral vector and 
its carried DNA should be stable in test tubes as well as in the body, nontoxic, and 
nonimmunogenic. 
 
To this end, several synthetic materials, including calcium phosphate [54-56] cationic 
liposomes [57-59], and cationic polymers like poly-L-lysine (PLL) [60] have been used for not 
only the enhancement of cell internalization and transfection but also efficient delivery of 
plasmid DNA to the specific area and the consequently high level expression.  
 
In the last decade, both branched [61][62] and linear [63][64] PEI have been introduced as 
cationic polymers for gene delivery. Compared with other polymer, PEI exhibits highly 
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efficient gene transfer without the need for endosomolytic or lysosomotropic agents. PEI 
itself can be taken up by endocytosis and escape from endosomes [65][66]. In the presence of 
sufficient PEI, plasmid DNA will condense from loose, random loops to a compact structure 
[67]. The extent of condensation highly depends on the ratio of polymer to DNA, and PEIs 
[68]. The sizes of PEI/DNA complexes have been found to be within the range 20–40nm 
using atomic force microscopy [67]. The surface charge of PEI and PEI/DNA complexes has 
been examined in terms of zeta potential [69]. It was found that while a certain sample of 
branched PEI had a zeta potential of 37mV in solution, this value was lowered significantly 
to 31.5 mV when the PEI was allowed to complex with DNA (at a 7.5:1 PEI nitrogen to DNA 
phosphate ratio). The surface charge of the transfecting colloid is thought to be an important 
factor in the complexes' association with plasma membranes. The ability of PEI to transfect a 
wide variety of cells has been well documented. Boussif et al. found PEI-mediated 
transfection in 25 different cell types, including 18 human cell lines as well as pig and rat 
primary cells [70]. Gene deliveries have been performed in vivo using adult [71] and 
newborn [72] mice as well as on Sprague-Dawley rats [73]. Abdallah et al. reported no 
morbidity in the mice examined over their 3-month experiment course [74].  
1.3.2 Gene manipulation of stem cell towards functional enhancement 
Combining bone marrow stem cell transplantation together with the genetic modification of 
therapeutic genes to the injured myocardium is an alternative strategy. Among the different 
cell types, MSC are being expected as one of cell sources usable for cardiac reconstruction 
because of their differentiation potential and ability to supply growth factors. However, the 
therapeutic potential of MSC is often hindered by the poor viability at the transplanted site. 
Transplantation of mesenchymal stem cells overexpressing Akt has been shown to improve 
the survival of the donor cell and prevent ventricular remodeling together with improved 
cardiac function [75]. Non-viral transfer of Hemoxygenase 1 gene to MSCs, providing 
cardioprotective properties resulted in a higher number of surviving MSCs for cardiac repair 
and regeneration (improved graft mesenchymal stem cell survival in ischemic heart with a 
hypoxia-regulated heme oxygenase-1 vector [76]. Co-overexpression of protein kinases 
B(Akt) and Angiopoietin-1 (Ang-1), by adenoviral transduction, was found to improve cell 
survival together with restoration of regional blood flow Stable therapeutic effects of 
mesenchymal stem cell-based multiple gene delivery for cardiac repair [77]. This multiple 
gene delivery study aimed to reach long term results 3 month after intramyocardial cell 
transplantation. Indeed extensive cell survival and myogenic differentiation were coupled 
with a significantly higher vessel density and smooth muscle cell covering (indicating 
maturation of newly formed vessels) in the study group compared to the control groups. 
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Thus, this genetic engineering technology is a promising strategy to enhance the therapeutic 
efficacy of MSC for ischemic heart disease. 
1.4 Conclusion 
Stem cell based cardiac therapy is a promising therapeutic approach towards the functional 
improvement and neo-angiogenesis. Recent clinical and experimental developments 
demonstrate intracardiac delivery of stem and progenitor cells could significantly reduce 
infarct size and improve cardiac contractility. However, various problems and questions 
remains including the poor cell survival, the heterogeneity of the clinical results, the unclear 
molecular mechanism of cardiac repair, and the timing of the cell delivery. In order to further 
improve the extent of functional improvement, genetic manipulation with various protective 
genes should be further explored.  
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Chapter 2 Nonviral Vector for Gene Delivery   
2.1 Transgene expression by intramuscular injection of PEI/DNA complexes (Publication 
A) 
2.1.1 PEI Could Mediate Retrograde Axon Gene Transfer 
PEI has shown high transfection efficiency both in vitro and in vivo. In particular, PEI may 
mediate DNA transfection in terminally differentiated nondividing neurons [78-81]. After direct 
brain injection, PEI/DNA complexes can provide transgene expression levels higher than those 
obtained with the human immunodeficiency virus (HIV)-derived vector and within the same 
range as that achieved with adenoviral vectors [79]. In view of the wide use of organic polymeric 
particles, such as dextran-coated microspheres or latex nanospheres, as retrograde tracers in 
neurons after endocytosis by axon termini [82], we investigated in this study whether the nonviral 
gene carrier PEI could be used to achieve gene transfer in the CNS after peripheral intramuscular 
injection. 
2.1.2 PEI Mediated Gene Transfer in the Brain Stem Following Tongue Injection 
To test the feasibility of gene delivery of PEI/DNA complexes to the CNS after intramuscular 
injection, we have chosen a well-characterized neuronal network, the hypoglossal system. Motor 
neurons of the hypoglossal nucleus in the brain stem innervate tongue muscles [83]. Marker gene 
(Luciferase plasmid) was complexed with PEI and injected into the tongue of the Wistar rats. We 
first tested PEI/pRELuc complexes at 15 mg of plasmid DNA with different charge ratios 
varying from 0 (i.e., naked DNA) to 25 PEI/DNA equivalents (Figure 2.1A) as well as PEI alone, 
produced no luciferase activity in the brain stem, indistinguishable from the tube background. At 
a charge ratio of 2 equivalents of PEI nitrogen per DNA phosphate where the overall charge of 
the PEI/DNA complexes would be negative at physiological pH, luciferase activity was 3×105 
relative light unit (RLU)/brain stem. Luciferase activity was significantly higher at a charge ratio 
of 10 equivalents, reaching 3 ×105 RLU/brain stem, and reached a maximum N/P ratio of 17 
equivalents, with 3×106 RLU/brain stem, and dropped to 3×104 RLU/brain stem when the charge 
ratio further increased to 25 equivalents. We then analyzed the effects of various amounts of 
DNA at a charge ratio of 17 equivalents of PEI nitrogen per DNA phosphate. A dose-dependent 
increase in luciferase activity was observed within the dose range of 5 to 20 mg pRELuc 
plasmid, with the highest value of 4 ×106 RLU per brain stem at 20 mg of DNA (Figure 2.1B).In 
terms of RLU/mg of DNA, the 10-mg dose produced 3×105 RLU/mg DNA (Figure 2.1C), 
roughly equivalent to 200 pg of luciferase. No further increase was observed with the 15 or 20 
mg of DNA dose on a perunit basis. 
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Figure 2.1 Luciferase activity in the brain stem after tongue injection of PEI/pRELuc 
complexes. A) Effects of PEI/DNA ratios. (B)Dose-dependent effects expressed per brain stem. 
(C) Dose dependent effects expressed per microgram of DNA injected. 
 
2.1.3 Localization of Transfected Cells in the Brain Stem 
To histologically determine the regions and cell types in the brain stem that expressed the 
transgene, a pcDNA3 plasmid containing the E. coli LacZ gene under the cytomegalovirus 
(CMV) promoter was complexed with PEI at N/P ratio 17/1 and injected into the tongue of the 
Wistar rats. The rats were sacrificed 2 days after injection. Cryostat sections of the brain stem 
were stained for β-Galactosidase (β-Gal) activity. Clearly labeled large neurons were evident in 
the hypoglossal structure (Figure2.2). Numerous motoneuron cell bodies and the proximal parts 
of their dendrites were densely stained. β-Gal activity was distributed throughout the whole 
hypoglossal nucleus in sagittal sections and β-Gal -positive cells accounted for about 90% of the 
total number of neurons in the hypoglossal nucleus. In contrast, no staining was detected in glial 
cells.Specificity of the β-Gal activity was confirmed in controls with either the human bcl-2 gene 
or the PEI polymer solution alone (Figure2.2).  
 
To assess the retrograde transport of DNA constructs from the tongue into the hypoglossal 
nucleus, DNA was extracted from the brain stem and amplified with PCR using the primers 
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specific for the E. coli LacZ gene. The plasmid DNA was detectable in the brain stem as early as 
12 h after the tongue injection and lasted for at least 14 days (Figure 2.3). 
 
Figure 2.2 Transgene expression in the hypoglossal nuclei of the rat brain stem. (A and B) Detection of b-gal 
expression 2 days after tongue injection of the PEI solution (A) and the PEI/pcDNA3.1 LacZ complex (B). 4V, 
fourth ventricle.  Original magnification: 3100. (C and D) Immunostaining of human Bcl-2 expression 2 days 
after injection of the PEI solution (C) and the PEI/pcDNA3 Bcl-2 complex at N/P ratio (D) into one side of the 
rat tongue.Fuorescence indicates the neurons overexpressing Bcl-2 mainly on one side of the hypoglossal nuclei. 
CC, central canal. (E and F) Immunofluorescence images of the GFAP expression in the hypoglossal nuclei. (E) 
Normal rat. (F) 2 days after tongue injection of the PEI/pcDNA3.1 LacZ plasmid complex at N/P ratio 30/1. 
Original magnification: 3400. 
. 
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Figure 2.3 Detection of pcDNA3.1 LacZ with PCR analysis. PCR amplification of DNA extracted from the brain 
stem after tongue injection of 15 mg plasmid complexed with PEI at N/P ratio 17/1 shows a 494-bp fragment of 
the E. coli LacZ gene. Lanes 1 and 10, size marker; lane 2, positive control, 200 ng pcDNA3.1/LacZ plasmid 
DNA used as template; lane 3, the negative control from rats injected with the PEI solution without the plasmid 
construct; lanes 4–9, various time points after tongue injection of PEI/LacZ complexes.  
 
2.1.4 Expression of the Therapeutic bcl-2 Gene in the Brain Stem 
To corroborate the finding with luciferase and lacZgenes, we have also used an anti-apoptosis 
gene, bcl-2(B-cell CLL/lymphoma 2), for further characterization. This gene may also have a 
potential therapeutic value in treatment of neuronal death. Two days after injection of PEI-
complexed pcDNA3 plasmid containing a human bcl-2 gene under the control of the CMV 
promoter into one side of the tongue, strong expression of the Bcl-2 protein was detected 
immunohistologically in numerous neurons of one hypoglossal nucleus (Figure 2.2). No Bcl-2-
positive cells were detected in lacZ gene or PEI polymer solution controls. The expression of the 
human Bcl-2 could also be detected using Western blotting, after microdissection of brain-stem 
tissue around the hypoglossal nucleus and protein extraction. The Bcl-2 was detectable as early as 
18 h after tongue injection and strongly expressed between 2 and 7 days. The expression 
continued for at least 14 days and became undetectable by 30 days (Figure 2.4 left). 
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Figure 2.4 Western blot analysis of human Bcl-2 expression. (Left) The kinetic change of human Bcl-2 protein 
levels in the rat brain stem after tongue injection. Lane 1, positive control, Bcl-2-transfected NT2 cells; lane 2, 
negative control from normal rat brain stem; lanes 3–8, rat brain stem collected 18 h and 1, 2, 7, 14, and 30 days, 
respectively, after tongue injection of 15 mg of Bcl-2 plasmid complexed with PEI at N/P ratio 17/1. (Right) 
Comparison of gene transfer efficiency of different DNA carriers. Rat brain-stem samples were collected 2 days 
after tongue injection. Lane 1, injected with PEI/Bcl-2 complex (N/P 5 17/1); lane 2, injected with PEI solution 
alone; lane 3, injected with naked Bcl-2 plasmid DNA; lane 4, Transfast/Bcl-2 complex; lane 5, Gene- 
PORTER/Bcl-2 complex. 
 
2.1.5 Discussion 
We demonstrated that PEI/DNA complexes can migrate by retrograde axonal transport to 
neuronal cell bodies after being internalized by nerve terminals in the muscle and confirmed the 
feasibility of nonviral gene delivery to the CNS via peripheral injection sites. This approach 
bypasses the blood–brain barrier and provides a practical therapeutic strategy that is non-invasive 
to CNS tissues. Neurotropic adenovirus and herpes simplex virus (HSV) can deliver genes to the 
CNS in the same way [84-92]. These viruses invade the nervous system by directly infecting 
axon terminals in the periphery and then travelling to the nerve cell somata in a retrograde 
manner. The frequency of neuron infection by retrograde transport of the virus vectors is in the 
range 50–100% for adenovirus [85] and 90% for HSV vector [92]. A similar transfection 
frequency was observed in the present study when PEI was used to mediate neuronal gene 
transfer following peripheral injection. However, the PEI-mediated gene expression lasted for 
only 2 weeks. Gene expression may continue from 30 days for adenovirus vectors [85] to about 
half a year for herpes simplex virus vectors, as detected by X-gal histochemistry. In terms of 
safety, PEI did not invoke any inflammatory responses or alterations in GFAP immunoactivity in 
the brain stem following tongue injection, consistent with the report that the polymer, at 
concentrations for efficient DNA transfection in neurons, caused no disruptive effect on either the 
CHAPTER 2                                                                            NONVIRAL VECTOR FOR GENE DELIVERY 
 
 14 
cell surface membrane or the electrical properties of the cells [80]. Replication-defective 
adenovirus would cause inflammation in the inoculated muscles, but it caused no pathology 
within the CNS, where the vector expressed a recombinant gene after retrograde axonal transport 
[86]. HSV vectors also did not invoke any inflammatory responses either at the peripheral 
inoculated site or at the gene expression site in the CNS [92]. A concern of using these viral 
vectors is related to the clinical situation of high titers of antibodies against the vectors induced 
by a preexposure to the viruses in some prospective patients, which may hinder the therapeutic 
efficacy of the vectors [93]. As well, this preexisting immune response or an enhanced immune 
response to the vectors following initial inoculation is a potential risk of repeated administration 
of the vectors [94]. The risk of immunological complications should, in theory, be low when 
synthetic DNA carriers such as PEI are used for gene transfer. Furthermore, this reduced risk 
would allow repeated injection of nonviral DNA complexes, therefore increasing the time span of 
transgene expression if needed. In addition to viruses, many proteins, metallic particulates, and 
polymer particles can be taken up by nerve endings and retrogradely transported to neuronal cell 
bodies [82]. Sahenk et al. have reported a lipofectin-mediated DNA transport to spinal motor 
neurons after muscular or nerve injection [95], with a transfection frequency of approximately 
18%. Consistent with this relatively low efficiency, two liposome systems used in the present 
study gave much lower levels of luciferase activities and Bcl-2 expression than PEI. Another 
nonviral DNA carrier that has been used to transport genes in a retrograde manner is PLL [96]. 
That study, although not involving any peripheral injection, has demonstrated that PLL-
condensed DNA particles mediated expression of reporter genes in the retina after administration 
at the cut end or axon terminals of the optic nerve in the brain. However, PLL, as well as 
chitosan, did not mediate any gene transfer in our system.  
PEI/DNA complexes are efficient at in vivo gene transfer into neurons after stereotactic injection 
into the brain. Under optimal transfection conditions for direct intracerebral injection, i.e., a 
charge ratio of 6 equivalents of PEI nitrogen per DNA phosphate, 4-3×105 RLU/mg DNA 
(equivalent to 0.4 ng of luciferase) was achieved [79], which was close to the values obtained 
using PEI to transfect neuronal cultures and newborn mouse brain (106 RLU/mg DNA) [78]. 
Transfection efficiencies in the brain stem observed in this study with a peripheral intramuscular 
injection (2-3×105 RLU/mg DNA or 0.2 ng luciferase per mg DNA injected) were close to what 
is achievable by direct intracerebral injection. The reason PEI gives the best result among the 
nonviral DNA carriers used in the present study is unclear. Size and charge of particles are 
probably among the factors that are critical for uptake by axonal terminals. A net positive charge 
may facilitate interaction with the cellular plasma membrane and endocytosis, but an excessive 
positive charge might cause entrapment of the DNA particles by the extracellular matrix. This is 
illustrated in the present study, in which the transgene expression increases with PEI/DNA ratio 
to the maximum, before dropping drastically at the highest ratio employed. The efficacy of PEI as 
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gene carrier in cell culture studies has been attributed to its proton sponge effect [78]. Comprising 
primary, secondary, and tertiary amino groups, PEI has been postulated to buffer the pH changes 
in endo/lysosomes to inactivate enzymes such as DNase 2 [97], which in turn leads to protection 
of the plasmid from enzymatic degradation. Since the subcellular structures that carry exogenous 
materials taken up by endocytosis to a neuronal cell body are endolysosomes or lysosomes, this 
buffering effect of PEI may be critical for DNA stability during a long distance axonal retrograde 
transport and, therefore, for the successful gene transfer observed in the present study.  The CNS 
is an organ with a great diversity of cell types. This sophisticated organ is composed of many 
regions, each of which has unique roles. Even highly limited injury to a small area of the CNS 
can damage a critical function, as evidenced in Parkinson’s disease, which results from the loss of 
dopamine neurons in a discrete anatomical region, the substantia nigra pars compacta. This 
feature of the CNS calls for therapies that can target specific locations or selected neuronal 
populations. By choosing a proper injection site, targeting some of the neuron populations deep 
in the CNS structure may be possible with retrograde transport-mediated gene delivery method. 
Jin et al. have shown that a defective HSV amplicon vector with a tyrosine hydroxylase promoter 
injected into the striatum may migrate by retrograde transport to the substantia nigra and mediate 
transgene expression in dopaminergic neurons [98]. Retrograde transport-mediated gene delivery  
potentially has a number of clinical applications in the peripheral nervous system as well, such as 
protecting degeneration of motor neurons caused by injury or genetic mutations; treating various 
pain states resulting from tissue injury, inflammation, or tumor invasion; and stimulating 
regeneration of damaged nerves.  
2.2 Receptor-mediated targeted gene delivery by recombinant peptide (Publication B) 
2.2.1 Introduction 
Targeted gene delivery to selected cell types is a crucial aspect of enhancing the specificity of 
transgene expression, for the purposes of gene therapy as well as functional genomics research. 
The transfection efficiency of a given dose of genetic material would be improved by augmenting 
entry into the desired cells and reducing wasteful uptake by nontarget cells. For therapeutic 
applications, targeted gene delivery would ensure therapeutic efficacy in the cells of interest 
while limiting side effects, including immune, inflammatory, and cytotoxic responses, caused by 
the expression of exogenous genes in nontarget cells. One approach to targeted gene delivery is 
to use ligand-associated delivery vectors to take advantage of the natural process of receptor-
mediated endocytosis. Many ligand–receptor systems have been investigated to date for targeted 
gene delivery 99][100][101]. Little has been established, however, on how to use such a system 
to target selected subtypes of neurons. 
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Neurons differ in their chemical signals and receptors, among which are nerve growth factor 
(NGF) and its receptors. NGF is an important molecule capable of promoting the development, 
growth, and survival of its responsive neurons, such as basal forebrain cholinergic neurons and 
sympathetic sensory neurons [102]. NGF is synthesized and secreted from neuronal target cells as 
noncovalently bound homodimers and functions through retrograde signaling after binding to its 
nerve-terminal-localized receptors and being internalized in endosomes [103]. NGF interacts 
selectively with one of the receptor protein tyrosine kinases, tyrosine kinases A (TrkA)[104]. 
Internalized TrkA after NGF stimulation could be identified in endosomes and transported to 
neuron cell bodies to activate its signaling targets [105][106]. NGF also binds with relatively low 
affinity to a 75-kDa transmembrane glycoprotein, p75NTR[107], a receptor with two main 
physiological functions: acting as a coreceptor to modulate Trk signaling and initiating 
autonomous signaling cascades that result in either the induction of apoptosis or the promotion of 
survival [107][108]. Since receptor-mediated endocytosis of NGF is a rapid and efficient process 
[103], NGF may serve as a candidate targeting ligand to direct gene vectors to TrkA- and/or 
p75NTR-positive cells. 
Extensive studies on the structural determinants of NGF in interacting with its receptors have 
identified NGF loop 1 as a key active site for p75NTR receptor-binding [109][110] and the N-
terminal region, loop 2, and loop 4 as important structures for binding to TrkA [111][112]. Based 
on these studies, small bioactive peptide mimetics using sequences from the NGF loop regions 
have been developed [113][114][115][116]. In the current study we developed a targeted gene 
delivery vector by combining the NGF-receptor-binding activities of NGF loops 1 and 2 with the 
DNA-binding function of SPKR repeats in a single chimeric peptide. We demonstrated that the 
peptide enhanced gene expression mediated by DNA/polymer complexes specifically in cells. 
 
2.2.2 Development of Chimeric Peptide SPKR4NL1-2 and Its Biochemical and Biological 
Effects 
SPKR4NL1-2 is a chimeric peptide containing a DNA-binding domain, SPKRSPKRSPKRSPKR, 
and a targeting domain incorporating the NGF hairpin motif of loops 1 and 2. The two parts are 
linked by an -helical linker, TYLSEDELKAAEAAFKRHNPT. The SPKR4 sequence, derived 
from the histone H1 DNA-binding domain, and the -helical linker were first used together by 
Fortunati et al. [117] in a DNA delivery vector. The linker is flanked by flexible glycine residues 
and serves to allow independent action of the DNA-binding and targeting domains. The targeting 
domain comprises a cysteine residue followed by amino acids 17–67 of human NGF, such that a 
disulfide bridge can form between this cysteine residue and C58 in NGF. Based on the crystal 
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structure of NGF [112], we judged that such a disulfide bond would help the targeting domain 
assume the native conformation of loops 1 and 2. 
The chimeric peptide was expressed with a His10-tag in the Escherichia coli strain BL21(DE3). 
The eluates from nickel-chelate affinity chromatography of E. coli lysates predominantly 
contained a protein similar in size to the expected molecular weight of SPKR4NL1-2 at 12.9 kDa. 
The produced chimeric peptide was able to activate TrkA and the ERK 1 and 2 proteins in its 
downstream signaling pathways (Figure 2.5). We observed TrkA phosphorylation by Western 
blot analysis of the cell lysate of TrkA-positive PC12 cells treated with SPKR4NL1-2, whereas 
this response was not elicited by similar treatment with a control peptide, (SPKR)4, that lacked 
the targeting domain (Figure 2.5A). We also observed enhanced phosphorylation of ERK 1 and 2 
after treatment with SPKR4NL1-2 at concentrations ranging from 1 to 8 M for 15 min, 
compared to that after treatment with 8μM (SPKR)4 control peptide (Figure 2.5B). To 
demonstrate that the ERK activation occurred specifically through TrkA phosphorylation, we 
pretreated cells with K-252a, a TrkA tyrosine kinase inhibitor, to see if ERK phosphorylation 
would be reduced. Figure 2.5C shows that ERK phosphorylation induced by 8 M SPKR4NL1-2 
was reduced and eventually eliminated by increasing concentrations of K-252a. 
SPKR4NL1-2 activates TrkA and ERK. PC12 cells preincubated in RPMI 1640 medium 
containing 0.5% FBS and 0.25% horse serum for 2 days were treated for 20 min with NGF or 
peptides diluted in serum-free RPMI 1640. The cell lysates were analyzed by immunoblotting 
using primary antibodies specific to either phospho-TrkA or phosphorylated ERK 1 and 2. (A) 
Phospho-TrkA Western blot. The cells were treated with NGF (20 ng/ml), SPKR4NL1-2 (8 M), 
SPKR4NL1-2/DNA complexes (8 μM, N/P ratio of 5), or (SPKR)4 (8 M). (B) Phospho-ERK 
Western blot. The cells were treated with NGF (20 ng/ml), various concentrations of SPKR4NL1-
2 from 1 to 8 M, or 8 M (SPKR)4. (C) A TrkA inhibitor blocks SPKR4NL1-2-induced ERK 
activation. The PC12 cells were preincubated with 0, 10, 20, 50, and 100 nM K-252a (TrkA 
tyrosine kinase inhibitor) for 10 min before treatment with NGF (20 ng/ml) or SPKR4NL1-2 (8 
μM). Molecular weights of protein standards are shown on the left. 
In response to NGF, PC12 cells stop proliferating and differentiate into sympathetic neuron-like 
cells. Within 2–3 days of NGF treatment, cell morphology changes and neurites can be seen 
projecting from the cells. We tested SPKR4NL1-2 to see if it could also promote neurite 
outgrowth in PC12 cells. We treated the cells with 8 M (SPKR)4 or SPKR4NL1-2 for 3 days. 
Compared to (SPKR)4, SPKR4NL1-2 displayed NGF-like bioactivity by promoting neurite 
outgrowth (Figure 2.6A and Figure 2.6B). We also investigated whether SPKR4NL1-2 shared the 
ability of NGF to promote survival of PC12 cells deprived of serum for 3 days. The addition of 
SPKR4NL1-2 (8 μM) to the serum-free medium maintained PC12 viability at 80% of the 
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maximal survival rate promoted by 10 ng/ml NGF (Figure 2.6C). The survival-promoting effect 
exhibited a dose–response trend over the range of 2–8 M polypeptide. 
SPKR4NL1-2 has NGF-like bioactivity. (A and B) SPKR4NL1-2 promotes neurite outgrowth. 
PC12 cells were treated with 8 μM (A) (SPKR)4 or (B) SPKR4NL1-2 for 3 days. (C) SPKR4NL1-
2 promotes survival of PC12 cells deprived of serum for 3 days. Different concentrations of 
SPKR4NL1-2, from 0 to 16 M, were added at the time of serum withdrawal and 10 ng/ml NGF 
was used as a positive control. Cell survival was estimated by an MTT assay and expressed as a 
percentage of maximal NGF-promoted cell survival. 
 
Figure 2.5 SPKR4NL1-2 activates TrkA and ERK. (A) Phospho-TrkA Western blot. The cells were treated 
with NGF (20 ng/ml), SPKR4NL1-2 (8 µM), SPKR4NL1-2/DNA complexes (8 µM, N/P ratio of 5), or 
(SPKR)4 (8 µM). (B) Phospho-ERK Western blot. The cells were treated with NGF (20 ng/ml), various 
concentrations of SPKR4NL1-2 from 1 to 8 µM, or 8 µM (SPKR)4. (C) A TrkA inhibitor blocks SPKR4NL1-
2-induced ERK activation. 
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Figure 2.6 SPKR4NL1-2 has NGF-like bioactivity. (A and B) SPKR4NL1-2 promotes neurite outgrowth. 
PC12 cells were treated with 8 µM (A) (SPKR)4 or (B) SPKR4NL1-2 for 3 days. (C) SPKR4NL1-2 
promotes survival of PC12 cells deprived of serum for 3 days. 
 
2.2.3 SPKR4NL1-2 Binds to Plasmid DNA and Enhances Gene Delivery to PC12 Cells 
We assessed the DNA-binding activity of SPKR4NL1-2 first in a DNA retardation assay. When 
mixed with 0.1 g of plasmid DNA, SPKR4NL1-2 dose-dependently reduced the mobility of 
DNA through an agarose gel under electrophoresis (Figure 2.7A), indicating that the peptide had 
bound to the DNA and reduced its charge/mass ratio. A significant reduction in DNA migration 
occurred when we used 1.25 g of peptide (Figure 2.7A). We also characterized the ability of 
SPKR4NL1-2 to bind to and condense DNA by measuring the quenching of fluorescence when 
intercalated ethidium bromide was displaced from DNA by the peptide. The fluorescence 
dropped sharply when 8 g of peptide was added to 0.8 g of DNA, indicating the amount of 
SPKR4NL1-2 needed for DNA condensation (Figure 2.7B). This result was in agreement with 
that from the DNA retardation assay. 
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Figure 2.7 SPKR4NL1-2 binds to and condenses plasmid DNA. (A) Electrophoretic mobility of plasmid 
DNA through a 1% agarose gel was reduced by SPKR4NL1-2 binding. (B) (C and D) Atomic force 
microscopy images of supercoiled plasmid DNA and SPKR4NL1-2/DNA/PEI600 complexes, 
respectively. 
Atomic force microscopy revealed, however, that SPKR4NL1-2 only partially condenses plasmid 
DNA at a nitrogen/phosphate (N/P) ratio of 2.5 (result not shown). The N/P ratio is defined as the 
number of protonatable nitrogen atoms per DNA phosphate group and is a frequently used 
measure of the charge balance in polycation or peptide/DNA complexes. For the purposes of 
calculating the N/P ratio for the peptides used in the study, we take the number of basic amino 
acid residues in the DNA-binding domain to be the number of "N" moieties per peptide molecule, 
that is, a total of 8 from the 4 lysine and 4 arginine residues in (SPKR)4. With the addition of 
low-molecular-weight polyethylenimine, PEI600, at an N/P ratio of 10, the loosely looped 
structure of free plasmid DNA molecules was no longer seen and compact nanoparticles in the 
size range of 100 to 200 nm were formed (Figure 2.7C and Figure 2.7D). 
Encouraged by the results from these DNA binding assays and the observation that SPKR4NL1-2 
could activate TrkA even after binding to DNA (Figure 2.5), we went further to test whether 
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SPKR4NL1-2 could improve gene delivery efficiency using NGF-receptor-positive PC12 cells. 
Complexes made from a luciferase-encoding reporter plasmid, pCAGluc, and SPKR4NL1-2 
alone had relatively weak transfection efficiencies, but the addition of polycationic polymer to 
fully condense the DNA created an effective gene delivery system. We chose PEI600 and poly-L-
lysine (PLL) for their DNA-condensing abilities and low background transfection efficiencies. In 
48-well plates, we transfected PC12 cells with triple complexes containing 0.5 g of pCAGluc, 
either PEI600 or PLL at an N/P ratio of 10, and various amounts of SPKR4NL1-2. To prepare the 
complexes, we added the peptide to the DNA in OptiMEM medium and incubated them for 30 
min at room temperature, after which we added the polycation and incubated the mixture for a 
further 30 min before use. We also added chloroquine, an endosomolytic agent, with the PLL-
containing complexes. Figure 2.8A shows that SPKR4NL1-2 enhanced PEI600-mediated gene 
transfer in a dose-dependent manner. Transgene expression using the highest amount of 
SPKR4NL1-2 tested was 5600-fold higher than that achieved with PEI600 alone. Similarly, with 
PLL-mediated gene delivery, transfection efficiency with the optimal amount of SPKR4NL1-2 
was 1000 times higher than without SPKR4NL1-2 (Figure 2.8B). 
 
Figure 2.8 SPKR4NL1-2 enhances polycation mediated gene transfection of PC12 cells. (A) PEI600 at an 
N/P ratio of 10. (B) Poly-L-lysine (PLL) at an N/P ratio of 10. 
2.2.4 Specificity of SPKR4NL1-2-Mediated Gene Delivery 
To examine the specificity of the SPKR4NL1-2 peptide in mediating gene delivery, we first 
compared the transfection efficiencies of the peptide and its control, (SPKR)4, in PC12 cells 
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using a reporter gene encoding an enhanced green fluorescent protein (EGFP). When we applied 
(SPKR)4/DNA/PEI600 triplexes, only a few EGFP-positive cells could be seen under a 
fluorescence microscope (result not shown). The number of EGFP-positive cells increased 
dramatically when we used SPKR4NL1-2/DNA/PEI600 triplexes, with approximately 30% of the 
PC12 cells exhibiting bright green fluorescence (result not shown). The result indicates that the 
targeting domain designed to recognize NGF receptors was essential to the enhanced gene 
expression mediated by SPKR4NL1-2. To demonstrate further that SPKR4NL1-2-mediated gene 
delivery depends on the peptide binding to NGF receptors, we studied the effect of adding 
exogenous NGF (200 ng/ml) during transfection with SPKR4NL1-2/pCAGluc/PEI600 complexes 
in PC12 cells.  Figure 2.9 shows that the presence of NGF reduced the efficiency of intracellular 
accumulation of labeled plasmid DNA and the luciferase gene expression by 82 and 97%, 
respectively. When SPKR4NL1-2 was replaced with (SPKR)4, the transfection efficiency was 
very low and NGF treatment had no significant effects. The action of NGF as a competitive 
inhibitor of SPKR4NL1-2/pCAGluc/PEI600 complexes indicates that SPKR4NL1-2-mediated 
gene delivery was targeted to NGF receptors.  
  
                               
Figure 2.9 NGF inhibits (A) DNA accumulation and (B) gene expression mediated by SPKR4NL1-2 in PC12 
cells.  
We subsequently tested cell-type specificity of SPKR4NL1-2-enhanced PEI600-mediated gene 
delivery on primary cultures of NGF-receptor-expressing cortical neurons and NGF-receptor-
poor glial cells isolated from 20-day-old embryonic rats. We first assayed cells for the expression 
of their high-affinity NGF receptor TrkA by flow cytometric analysis using an antibody against 
TrkA. Approximately 48% of rat primary cortical neurons were TrkA positive, while almost no 
primary cortical glial cells were positively stained (Figure 2.10A). We then transfected cortical 
neurons and glial cells in 48-well plates with SPKR4NL1-2/pCAGluc/PEI600 or 
SPKR4/pCAGluc/PEI600 complexes containing 0.25 g/well pCAGluc, peptide at an N/P ratio of 
2.5, and PEI600 at an N/P ratio of 5. Figure 2.10B shows that gene delivery by PEI600 alone was 
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negligible in both neuronal and glial cells. When the control peptide, (SPKR)4, was added to the 
complexes, the additional DNA-condensing ability enhanced transgene expression in both types 
of cells, although the impact was higher in glia than in neurons. Triple complexes containing 
SPKR4NL1-2 were nine times more effective in neurons than (SPKR)4 triple complexes, whereas 
in glial cells, there was essentially no difference in performance between SPKR4NL1-2 and 
(SPKR)4. 
 
Figure 2.10 SPKR4NL1-2 mediates gene delivery to primary neurons and glial cells. (A) Flow cytometric 
analysis of the percentage of cells expressing TrkA receptors. (B) Luciferase gene expression.  
 
We compared SPKR4NL1-2 with commonly used nonviral gene carriers PEI25kDa and 
Lipofectamine2000 in terms of gene delivery efficiency in primary cortical neurons and glial 
cells (Figure 2.11). With optimal carrier/DNA ratios, Lipofectamine2000 gave the highest 
transfection efficiency in both types of cells among three tested gene carriers. Although 
SPKR4NL1-2 was less efficient in glial cells compared with PEI25kDa, it mediated the transgene 
expression in neurons comparable to that of PEI25kDa. Notably, SPKR4NL1-2 was the only one 
among the three carriers giving a much higher level of gene expression in neurons compared to 
glial cells (Figure 2.11A). The level in neurons mediated by this peptide was 587% of that in glial 
cells (Figure 2.11B). The corresponding percentages produced by Lipofectamine2000 and 
PEI25kDa were 23 and 20%, respectively (Figure 2.11B). The difference suggested that 
SPKR4NL1-2 preferentially functioned in neurons over glial cells. 
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Figure 2.11 Comparison of various gene carriers for transfer efficiency in primary neurons and 
glial cells. Luciferase activities were measured 24 h later and are shown in RLU/mg protein in 
(A) and the percentage of neuronal readings from glial RLU in (B). 
 
2.2.5 SPKR4NL1-2-Mediated in Vivo Gene Delivery to Dorsal Root Ganglia (DRG) 
To evaluate the efficacy of SPKR4NL1-2-mediated transfection in vivo, we injected gene delivery 
complexes intrathecally into the lumbar regions of the rat spinal cord. The lumbar spinal cord is 
in general an NGF-receptor-poor region. A large portion of dorsal root ganglion (DRG) neurons, 
however, expresses TrkA receptors [118]. As DRGs lie at the distal end of the dorsal root of the 
spinal cord inside the apex of the dural sleeve [119], intrathecally applied peptide/DNA 
complexes in the cerebrospinal fluid would be able to penetrate into the DRG. We injected 
complexes containing 4 g of pCAGluc per rat. We dissected the lumbar spinal cord and the 
lumbar DRG 3 days later and analyzed them for luciferase activity. While luciferase activity was 
barely detectable in the spinal cord, DRG transgene expression produced by SPKR4NL1-
2/pCAGluc/PEI600 complexes was 9 to 14 times that mediated by the pCAGluc/PEI600, 
(SPKR)4/pCAGluc/PEI600, or pCAGluc/PEI25kDa controls (Figure 2.12A). 
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Figure 2.12 SPKR4NL1-2 mediates in vivo gene delivery to dorsal root ganglia 
(DRG) 3 days after injection. (A) Luciferase gene expression. Results are expressed 
in RLU/mg protein. **P < 0.01 compared to the rats treated with DNA complexed 
with (SPKR)4/PEI600. (B) Confocal images of luciferase expression in neurons in 
DRG. 
To evaluate in vivo cell-type specificity of SPKR4NL1-2-mediated transfection, we carried out 
immunohistochemical double labeling of DRG sections using antibodies against luciferase to 
visualize transfected cells and antibodies against the neuron-specific nuclear protein (NeuN) to 
visualize neurons. The results demonstrated that almost all of the transfected cells in DRG were 
neurons (Figure 2.12B). 
2.2.6 Discussion 
To develop a gene delivery system capable of targeting specific subtypes of neurons in complex 
organs like the brain and the spinal cord, the present study has designed, developed, and tested a 
chimeric peptide, SPKR4NL1-2, that can bind to DNA, direct DNA complexes to cells equipped 
with NGF receptors, and mediate intracellular gene delivery. Several lines of evidence implicate 
the involvement of NGF receptors in gene delivery mediated by this peptide. First, it possessed 
NGF-like bioactivity in NGF-receptor-positive PC12 cells, even after binding to DNA, and its 
activity in signal transduction was blocked by the TrkA inhibitor K252a. Second, the peptide 
dose-dependently mediated gene delivery to cells expressing NGF receptors, but had no 
enhancement effect on the cells lacking these receptors. Third, only chimeric polypeptides 
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containing both a receptor-targeting domain and a DNA-binding domain were functioning in 
mediating gene expression; the targeting domain contains NGF loops 1 and 2, two domains 
known to be important in interacting with TrkA and p75NTR. Fourth, gene transfer to NGF-
receptor-expressing cells was inhibited by co-incubation with an excess amount of NGF. Fifth, 
the gene delivery vector was able to target a region expressing NGF receptors (the DRG) even in 
a complex in vivo environment, a feature making it promising for clinical application.  
Small peptide mimetics of NGF using sequences from its hairpin loop regions have been 
developed to activate NGF-receptor-related signal transduction and promote NGF-like 
neurotrophic effects [110][113][114][115][116][120]. These peptide mimetics need to be 
structural analogs, not just sequence analogs, of NGF loops to be biochemically and biologically 
active, and hence, cyclization is a common feature. Differing from the short, cyclized loops used 
in the previous studies, an NGF hairpin motif, a supersecondary structural element built up from 
two adjacent strands that are connected by a loop region, was utilized in the present study. The 
A and B strands of NGF are connected together at one end by NGF loops 1 and 2. These 
elements of the hairpin motif, comprising amino acids 17–67 of NGF, have been used as the 
targeting ligand of our chimeric peptide-based gene delivery vector. By using a hairpin motif 
instead of a short, artificially cyclized loop, we expect the native loop conformation to be well 
stabilized by hydrogen-bonding between strands, while the flexibility required for induced-fit 
ligand recognition by NGF receptors will be better conserved. 
NGF, like other members of the neurotrophin family, is a noncovalently bound homodimer that 
stimulates dimerization of its receptors, thus triggering a signal cascade and inducing receptor-
mediated endocytosis [121-123]. In designing short peptide mimetics of neurotrophins, much 
work has been put into emulating this effect using cyclic dimers or bicyclic compounds [110] 
[113-116]. In contrast, the peptide SPKR4NL1-2 used in this study is monomeric and monovalent 
but exhibits detectable NGF-like bioactivity. During its design, we anticipated that after the 
polypeptide was combined with DNA, nanoparticle formation would result in many monovalent 
ligands being tethered close together on the particle surface, such that neighboring pairs of 
ligands would be able to facilitate receptor dimerization. Targeted gene delivery in the CNS is 
currently achieved simply through direct stereotactic injection of naked DNA or gene vectors into 
well-defined anatomical locations, transducing various types of cells around the injection site. 
Retrograde axonal transport of viral or nonviral gene vectors offers another way to target neurons 
in different regions by choosing an appropriate injection site either in the periphery or in more 
accessible regions of the CNS. This method, however, transduces all projection neurons and does 
not distinguish between subtypes of neurons. When used in combination with the above injection 
procedures, the NGF-receptor-targeting peptide reported here might be able to direct gene vectors 
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specifically to selected neurons in a particular region. This approach can potentially be used 
advantageously in gene therapy to treat disorders in which neurons expressing NGF receptors are 
affected. In Alzheimer's disease, the neurons with the most prominent pathological changes are 
basal forebrain cholinergic neurons, which express TrkA [124][125]. A gene delivery system that 
targets TrkA may therefore help to transfer therapeutic genes into the neurons to augment 
cholinergic functions. 
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Chapter 3 Stem Cell for Cardiac Repair  
 
3.1 Human cord blood cells induce angiogenesis following myocardial infarction 
(Publication C) 
3.1.1 Introduction 
Umbilical cord blood contains circulating stem/progenitor cells with cellular characteristics that 
are quite distinct from those of bone marrow and adult peripheral blood [126][127]. The 
frequency of hematopoietic stem cells and progenitor cells equals or exceeds that of marrow and 
greatly surpasses that of adult peripheral blood [128]. Stem cells from cord blood expand longer 
in culture, produce larger hematopoietic clones in vitro, and have longer telomeres [129][130]. 
Cord blood also contains mesenchymal progenitor cells capable of differentiating into marrow 
stroma, bone, and muscle, and the immaturity of neonatal cells compared with adult cells may 
translate into greater cell plasticity [131]. In addition, cord blood cells are usually not infected 
with cytomegalovirus or Epstein–Barr virus, as is often the case with marrow cells. For all those 
reasons, cord blood is considered as a valuable source of cells with a potential for tissue repair in 
response to injury [132]. However, the homing and migration characteristics of cord blood cells 
as well as their capacity for transdifferentiation into various target organ cells remain largely 
unexamined [133]. We therefore studied the organ-specific homing pattern of human 
mononuclear cord blood (hUCB) cells in a NOD/scid (non-obese diabetic severe combined 
immunodeficiency) -mouse model and tested the hypothesis that hUCB cells specifically migrate 
to the heart after myocardial infarction(MI), participate in tissue remodelling, and possibly 
facilitate regeneration processes. Moreover, we investigated whether SDF-1, which has been 
implicated in stem cell homing processes [134][135], is involved in selective cell migration to 
ischemic myocardium. 
3.1.2 Cord Blood Cell Characteristics 
Thirty cord blood samples were used for mononuclear cell separation. The mean collection 
volume was 44.6 ± 4.1 ml, containing between 99 x 106 and 294 x 106 cells by manual counting 
after Ficoll centrifugation and washing (mean 208 x 106 ± 58 x 106 cells). Cell viability ranged 
between 42% and 98% (mean value=78 ± 18%). A representative FACS analysis is depicted in 
Figure 3.1, showing the forward versus sideward scatter plot (A) and the proportion of 
CD14+/CD45+ cells. CD45+ cells are gated (C) and the percentage of CD34+/CD133+ cells among 
the CD45+ leukocytes is shown in (D). Overall, the percentage of CD45+ cells ranged between 
43.8% and 91.1%. Percentages of CD34+ cells (including CD34+/CD133+ and CD34+/CD133neg 
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cells) ranged between 0.11% and 1.1% (0.63 ± 0.5%). The average percentage of CD14+ 
monocytes was 14.9 ± 0.3%. 
 
 
 
 
Figure 3.1 Representative FACS analysis 
of mononuclear cells obtained from 
human cord blood, showing the forward 
versus sideward scatter plot (A) and 
CD45+ cell gating (C). The proportion of 
CD14+/CD45+ cells is shown in (B), and 
the percentage of CD34+/CD133+ cells 
among the CD45+ leukocytes is depicted 
in (D). In this case, 48.3% of the MNCs 
were CD45+ (C), 0.8% was CD34+, and 
0.6% were CD34+/CD133+ cells (D), and 
14.9 of the CD45+ cells were CD14+ 
monocytes (B). Overall, the percentage of 
CD34+ hematopoietic stem cells ranged 
between 0.11% and 1.1%.  
 
 
 
Figure 3.2 Human cord blood cell trafficking to the infarcted myocardium was detected by PCR using human-
specific primers D7A and D7B of -satellite of chromosome 7 Locus D7Z. (A) Shows that 4 out of 6 MI+ mouse 
hearts were hDNA+ 24 h after intravenous injection of human cord blood MNCs. As shown in panel (B), PCR for 
hDNA was negative in all hearts of MI– mice that had also undergone cell injection. Numbers (1–6) indicate 
different animals. M, molecular weight marker; N1, negative control (animal with myocardial infarction and 
without cell injection); N2, negative control (animal without myocardial infarction and without cell injection); P, 
positive control (human DNA used as template). 
 
3.1.3 Detection of hDNA  
 
Following intravenous implantation of human cord blood mononuclear cells, human DNA was 
detected in bone marrow, liver, and spleen of all animals (MI+ and MI–) at all time points. There 
was, however, a striking difference regarding hUCB cell engraftment in the heart (Figure 3.2). In 
10 out of a total of 19 MI+ mice PCR confirmed the presence of hDNA, while no hDNA was 
detected in any of the MI– hearts (P=0.002). (24 h, 4 out of 6 MI+ mice; 1 week, 3 out of 6 MI+ 
mice; 3 weeks, 3 out of 7 MI+ mice). 
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3.1.4 Myocardial infarction 
 
Eight animals (25%) died preoperatively prior to hUCB cell injection and were excluded from 
further analysis. As determined by light microscopy following H&E and Picrosirus Red staining, 
left anterior descending coronary artery (LAD) ligation consistently resulted in transmural 
myocardial infarction, exhibiting typical histological changes including thinning of left 
ventricular free wall and extensive collagen deposition 3 weeks after myocardial infarction. The 
average infarct size was 47 ± 7% in untreated MI+ mice and 39 ± 3% in the cell-treated MI+ 
mice, and this difference proved statistically significant (P=0.016;). Figure 3.3 depicts 
representative left ventricular sections 3 weeks following LAD ligation with (Figure 3.3A) or 
without (Figure 3.3B) cord blood cell injection. Within the group of cell-treated MI+ mice, infarct 
size was compared between hearts that were positive for hDNA by PCR, and those that were 
PCR-negative. Indeed, we found that infarct size was significantly smaller in MI+/cell-
treated/PCR+ hearts than in MI+/cell-treated/PCR– hearts. Overall, loss or gain of ventricular 
tissue was also assessed by determining the ratio of heart weight (HW) to body weight (BW). The 
body weight did not significantly differ between groups. In MI+ mice with cord blood cell 
injection, the HW/BW ratio was slightly lower than in MI+ mice without cell injection, perhaps 
indicating less compensatory myocardial hypertrophy in cell-treated mice. As determined by 
computerized color analysis of the Sirius red stained sections, collagen content was lower MI+ 
hearts of hUCB-treated mice than in MI+ hearts of mice without cell treatment (P=0.02). 
3.1.5 Morphology of hUCB-derived cells 
 
In hDNA-positive hearts we also traced hUCB-derived cells by immunostaining with anti-human 
nuclear antigen (HNA) and anti- human leukocyte antigen (HLA) class I antibodies. Human cord 
blood-derived cells were indentified in the heart of a MI+ mouse sacrificed 3 weeks after cell 
transplantation. HNA+ and HLA+ cells were found widely distributed in the myocardium. 
Typically, isolated cells and sometimes clusters of more than 10 transplanted cells were found in 
the subepicardial and subendocardial infarct tissue. In 100 random fields per section, the 
proportion of HNA+ and HLA+ cells was approximately 0.01–0.1% of the native mouse cells. 
When examined at higher magnification, HNA+ and HLA-I+ cells were typically localized in the 
immediate vicinity of myocardial blood vessels. Double-immunofluorescent staining with anti-
HLA class I and anti-CD31 antibodies revealed that at least that some of the hUCB cells appeared 
to display the phenotype of endothelial cells. Occasionally, small blood vessels of capillary 
morphology presented a human–mouse micro-chimerism (Figure 3.4), consisting of both HLA-I+ 
and HLA-Ineg endothelial (CD31+) cells. 
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Figure 3.3 Picrosirus red staining 
of transverse sections through 
mouse hearts 3 weeks following 
ligation of the LAD coronary 
artery. Thinning of the left 
ventricular free wall and extensive 
collagen deposition in scar tissue 
(red) is noted. (A) Mouse heart 
following LAD ligation and cord 
blood cell injection, and (B) 
without cell injection. 
 
 
Figure 3.4 Immunfluorescent visualization of a capillary in the infarct border zone. (A) Anti-CD31 staining (green 
fluorescence). (B) Anti-HLA class I staining (red fluorescence). (C) Both images merged give the impression of a 
human (yellow) and mouse (green) vascular chimerism (original magnification 400X). 
3.1.6 Capillary Density 
Capillary density in the infarct border zone as well as in myocardium remote from the infarct was 
determined following immunostaining with anti-mouse Factor VIII antibody. Representative 
images are shown in Figure 3.5. Infarcted myocardium of mice without hUCB cell transplantation 
contained few capillaries, whereas capillary density in MI+ mice that had undergone hUCB cell 
transplantation was approximately 20% higher (Figure 3.4). In the cell transplanted group, the 
average vascular density within the infarct border zone was 6.19 ± 0.2 vessels per high power 
field (HPF; 400 ×), while in control hearts (MI+, no cell treatment) there were 5.33 ± 0.5 
vessels/HPF (p=0.033). In myocardium remote from the infarct area, capillary density was 5.41 ± 
0.49 per HPF in MI+ mice with hUCB cell transplantation, which was again significantly higher 
than in MI+ mice without cell injection (4.3 ± 0.57/HPF, p=0.013). Most of the vessels exhibiting 
Factor VIII-positive endothelium were capillaries with an internal diameter 20 µm. The size of 
the capillaries in the infarct area ranged between 5 µm and 20 µm, with a greater variation in 
diameter than observed in normal myocardium (10 µm to 20 µm). We also compared peri-infarct 
capillary density in MI+ mice with cord blood cell injection that were PCR positive with those 
that were negative for hDNA. Capillary density was indeed higher in PCR-pos cell-treated MI+ 
mice than in PCR-neg cell-treated MI+ mice (6.6 ± 0.2 vs. 5.8 ± 0.5 vessels/HPF, P=0.028). 
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Figure 3.5 Quantitative capillary density data based on Factor VIII immunostaining. Capillaries were counted in 
the infarct border zone and in myocardium remote from the infarct by an investigator who was blinded with 
respect to the group allocation. In either situation, capillary density was significantly higher in cell-treated 
animals (data are mean ± S.D.). 
 
3.1.7 SDF-1 Expression 
To test the hypothesis that upregulation of SDF-1 occurs in infarcted myocardium and hence may 
contribute to hUCB-derived cell migration in ischemic hearts, we compared the expression level 
of SDF-1 mRNA in hearts 24 h after myocardial infarction with that in untreated control hearts. 
Figure 3.6 shows that the level of the SDF-1 mRNA in myocardium is approximately 7-fold 
higher after myocardial infarction (p<0.0001).  
 
 
Figure 3.6 Expression of SDF-1 in murine myocardium 24 h after myocardial infarction (MI+), and in 
myocardium of sham-operated animals (MI–). SDF-1 mRNA expression was evaluated by real-time RT-PCR (B) 
and RT-PCR was performed to confirm the correct size of the amplification product and the absence of non-
specific bands (A). Data represent mean ± standard deviation of 6 experiments. 
3.1.8 Discussion 
This study demonstrates that intravenously administered human umbilical cord blood cells 
migrate to and engraft in the heart of (NOD)/scid mice only following myocardial infarction. 
While there was no evidence of cardiomyocyte formation, hUCB cells appear to be involved in 
angiogenic processes. Following cell administration, capillary density in hearts with myocardial 
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infarction is moderately increased, but few hUCB-derived cells actually incorporate in neo-
vessels, whereas most of the human cells are located in the perivascular interstitium. Cord blood 
cell injection also appeared to beneficially influence infarct size and collagen deposition, 
provided there is effective homing of hUCB cells to the ischemic heart. Since myocardial 
infarction also led to a marked upregulation of SDF-1 expression in the heart, we assume that 
SDF-1 is at least partly responsible for the selective hUCB cell trafficking to ischemic hearts, 
although the study design does not allow for proof of a cause–effect  relationship.  
Cell therapy for cardiac regeneration is currently under intensive investigation. The initial 
enthusiasm regarding the cardiomyogenic potential of adult stem cells [136] has faded 
[137][138], but substantial evidence obtained in large animal studies and even clinical pilot trials 
indicates that hematopoietic cells nevertheless exert beneficial effects in ischemic myocardium 
[139][140]. Trafficking of bone marrow-derived cells to the heart is a phenomenon that has been 
demonstrated in various experimental models [141] as well as in human heart transplant patients 
[142]. The vasculogenic potential of cord blood cells has previously been assessed in several 
studies. In in vitro experiments using CD34+/CD133+ human cord blood cells, Pomyje and 
colleagues demonstrated that those express angiopoietin-1, angiopoietin-2, and vascular 
endothelial growth factor as well as their receptor mRNAs, supporting a role of these cells in 
regulation of angiopoiesis [143]. Muohara et al. have described that transplanted cord blood-
derived endothelial precursor cells augment postnatal neovascularization in the ischemic hindlimb 
[144], and Pesce et al. observed endothelial and also myogenic differentiation of hUCB-derived 
stem cells in ischemic limbs [145]. Recently, Le Ricousse-Roussanne et al. reported that ex vivo 
differentiated endothelial and smooth muscle cells from human cord blood progenitors home to 
the angiogenic tumor vasculature [146]. In our model, the inoculated hUCB cells appear to be a 
source of neovascularization of ischemic myocardium, since they differentiated into endothelial 
cells, formed chimeric capillaries, and presumably participated in post-infarct remodelling, 
angiogenesis, and maturation of the scar. To what extent these processes will translate into 
functionally relevant myocardial regeneration as has been described using human marrow-derived 
cells in athymic rats [139] remains to be determined. At first glance, our observation regarding 
the formation of a human/mouse vascular micro-chimerism appears to contradict the report by 
Ziegelhoeffer et al., who demonstrated that bone marrow-derived cells do not incorporate into the 
adult growing vasculature [147]. However, it should be noted that (i) we used cord blood cells, 
not bone marrow-derived cells, (ii) we utilized a myocardial infarction model, not a hindlimb 
ischemia or tumor model as these authors did, and (iii) we found rather few neo-vessels that 
stained positive for human cell markers, whereas most of the myocardial neovascularization 
appeared to originate from native mouse endothelial cells, with donor cells mainly located in the 
perivascular interstitium. Although we found evidence that hUCB-derived cells are able to 
incorporate in growing vessels in principle, much of the angiogenic host tissue response is most 
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likely do to local secretion of cytokines and growth factors [147][148]. Since 30–70% of the cord 
blood cells that we detected had maintained their hematopoietic phenotype, they may very well 
have been able to modulate the immune/inflammatory response to myocardial infarction.  
The mechanisms underlying homing and engraftment of stem cells and progenitor cells in various 
target organs are not fully understood, but in situ chemokine and cytokine expression probably 
plays a role. A noted chemokine is stromal cell-derived factor-1, also known as pre-B cell growth 
stimulating factor. Under normal conditions, bone marrow stromal cells such as bone-forming 
osteoblasts produce and secrete high levels of SDF-1. SDF-1 and its receptor CXCR-4 are 
believed to facilitate stem cell adhesion to microvessel endothelium and trans-endothelial 
migration in the infarct border zone of infarcted myocardium [135]. We assume that after 
myocardial infarction, the local expression level of SDF-1 is upregulated, increasing the 
myocardial concentration of SDF-1 and attracting circulating CXCR4 positive cells [134]. 
However, the molecular mechanism of SDF-1 secretion by ischemic heart cells and its 
chemoattractant action on stem cells is still under investigation. Cord blood cell trafficking to the 
ischemic heart is not an all-or-nothing phenomenon, since hDNA was detectable only in 10 out of 
19 MI+ hearts. In intact biological systems subjected to complex pathophysiologic stimuli, the 
molecular and cellular response is usually gradual, and chemokine expression may need to reach a 
certain threshold to attract relevant numbers of progenitor cell. The variables involved are 
manifold: Initial infarct size, magnitude of cytokine expression per unit ischemic tissue, or the 
responsiveness of injected hUCB cells may vary considerably. The necessity of relevant hUCB 
cell trafficking to the ischemic heart for a protective or regenerative effect on the myocardium is 
underscored by our finding that infarct size is significantly smaller and capillary density is higher 
in hearts of cell-treated MI+ mice that were PCR+ for hDNA than in those that were PCR–.  
Naturally, our study possesses several methodological limitations. We did not determine the 
functional relevance of myocardial hUCB cell migration in terms of left ventricular contractility 
or relaxation properties. Furthermore, the co-localization studies that showed the incorporation of 
hUCB-derived cells into murine neo-vessels were performed using fluorescence microscopy, 
which has been implicated in producing false-positive results [138] [147]. Another possible pitfall 
is the complete absence of hUCB-derived cells in normal control hearts and the presence of 
hUCB-derived cells in approximately 50% of the ischemic hearts. Would these data rely on 
microscopy-based methods such as immunohistology or in situ hybridisation only, one could 
argue about an inherent lack of sensitivity. Therefore, we chose to perform PCR for detection of 
human DNA in mouse hearts, and used human chromosome specific α-satellite primers to track 
cells. In preliminary experiments, we amplified human alpha satellite DNA from in vitro somatic 
cell hybrids containing only a handful of human cells. PCR analysis with centromere-specific 
primer sets can be performed to characterize somatic cell hybrids more effectively and perhaps 
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more accurately than by cytogenetic means. To our knowledge, this is the first time that a 
chromosome specific α-satellite DNA primer has been used to distinguish different genetic 
backgrounds, and we are confident that PCR-negative murine myocardium does in fact not 
contain a relevant number of hUCB-derived cells.  
  
3.2 Comparation of human CD133+ cells derived from bone marrow and from cord blood in 
a SCID-mouse model (Publication D) 
The concept of cardiac cell transplantation to improve myocardial function is tremendously 
attractive, and it has repeatedly been suggested that cells derived from skeletal muscle, bone 
marrow, blood, or other tissues might have a regenerative capacity in the mammalian heart. 
Among those, CD34+ or CD133+ progenitor cells are of particular interest, because the 
corresponding antibodies can be used in clinical enrichment protocols, applying methods for 
primary cell isolation that comply with standard regulations for clinical use. Nevertheless, few 
experimental studies have systematically assessed the myocardial regeneration potential of 
CD133+ cells in vivo. We therefore sought to determine the functional and histologic 
consequences following direct intramyocardial delivery of human CD133+ cells derived from 
bone marrow and from cord blood in a SCID-mouse model of left ventricular cryoinjury. 
3.2.1 Characteristics of CD133+ Cells from Cord Blood and Bone Marrow 
The average purity of the CD133-enriched cell products was 91.2±4% (CD133+ cells in percent 
of total mononuclear cells), with no difference between UCB and BM-derived cells. To test 
whether the CD133-enriched cell products from UCB and BM had a different composition of 
subpopulations, cells were counted by flow cytometry following labelling of CD34, CD133, 
CD45, and CD117. Representative results are shown in Figure 3.7. Cell viability was quantified 
by propidium iodide staining, and was consistently higher than 90%. There were no differences in 
the expression of CD45 and CD34. BMCD133 expressed the CD133 antigen not as strong as 
UCBCD133 cells. On average, 70% of the BMCD133 cells were also positive for CD117, whereas 
only up to 35% of the UCBCD133 cells were CD117+. The frequency of BMCD133+/CD117+ cells in 
every examined BMCD133 cell product was markedly higher than that of UCBCD133+/CD117+ cells 
among the UCBCD133 cell products (Figure 3.7A and B).  
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Figure 3.7 (A) Multicolor flow cytometric analysis of CD133+ cells derived from bone marrow. First row, left: 
CD133-selected cells were found to have a dim expression of CD133 and are all CD34+; right: isotype control. 
Second row, left: BMCD133 cells are also CD45 dim; right: isotype control. Third row, left: 68.9% of all BMCD133 
cells were found to be positive for CD117; right: isotype control. (B) Multicolor flow cytometric analysis of 
CD133+ cells derived from cord blood. First row, left: All UCBCD133 positive cells were found to be positive for 
CD34, right: isotype control; Second row, left: All UCBCD133 cells also express CD45; right: isotype control. 
Third row, left: 34,1% of all UCBCD133 cells were found to be positive for CD117; right: isotype control. 
  
3.2.2 In Vitro Plasticicty Studies 
When cultivated on matrigel coated culture dishes and exposed to VEGF, both BMCD133 and 
UCBCD133 cells formed capillary network-like structures after 14 days of culture (Figure 3.8A and 
B). Approximately 75% of the thus cultivated cells expressed endothelial cell-specific von 
Willebrandt factor (vWF)(Figure 3.8C and D). Moreover, most of those cells were also positive 
for uptake of Dil-ac-LDL (Figure 3.8E-H), further evidence of an endothelial cell-like 
differentiation commitment. In this respect, no apparent difference in behavior was found 
between BMCD133 and UCBCD133 cells. On the other hand, after up to 21 days exposure to 
myogenic differentiation conditions, neither with or without 5-Azacytidine, no expression of β-
myosin heavy chain and no spontaneously beating cell was detected in any of the samples, 
indicating that differentiation in myocyte-like cells, at least under the given in vitro conditions, 
did not occur. 
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Figure 3.8 In vitro differentiation 
of CD133 cells towards an 
endothelial cell phenotype. (A) 
After cultivation on Matrigel for 
2 weeks, UCBCD133 cells form 
capillary-like tubules (scale 
bars=100 µm). (B) BMCD133 cells 
display the same behaviour. (C, 
D) Immunostaining of UCBCD133 
(C) and BMCD133 (D) derived 
endothelial progenitor cells for 
vWF (red fluorescence, scale 
bars=50 µm). (E, F) Cellular 
uptake of acLDL (green 
fluorescence) by endocytosis in 
BMCD133 derived endothelial cells 
(F, differential interference 
contrast image). (G, H) The same 
observation in UCBCD133 derived 
cells (scale bars=20 µm). 
  
3.2.3 Survival 
Overall, left ventricular cryoinjury produced an early mortality of approximately 30% within the 
first 4 h after completion of the surgical procedure, and there was no difference in peri-procedural 
mortality between control and cell-treated groups (Figure 3.9). In sham operated animals no 
mortality was observed. During the subsequent phase of recovery from the operation, another 
third of the mice in the cryoinjury control group died (late mortality=32%). This delayed 
mortality was abolished by both BMCD133 and UCBCD133 cell transplantation (p<0.05 vs. Control). 
In the time-related Kaplan–Meier analysis, survival of mice in the cryolesion control group was 
43% (70% confidence interval 33–53%) at 28 days, 75% (64–86%) in UCBCD133 cell treated mice, 
and 68% (60–74%) in BMCD133 cell treated mice. Mean survival time was computed as 13 days 
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(70% confidence interval 11–16 days) for control mice, 19 (16–22) days for BMCD133 cell treated 
mice, and 21 (18–24) days for UCBCD133 cell treated mice. Post-mortem histological analysis of 
mice that died during the observation period revealed the typical transmural cryolesion of the left 
ventricle.  
 
Figure 3.9 Kaplan–Meier estimated survival of 
mice with 28 days after cryoinjury of the left 
ventricle. Surgical mortality was similar in all 
cryoinury groups. Other than that, no mice died 
late after simultaneous injection of UCBCD133 
cells, and only one mouse died after delivery of 
BMCD133 cells. In contrast, mice without cell 
treatment (control) had a marked mortality 
during the first postoperative week. In the sham 
operated group (thoracotomy without cryolesion) 
no animals died peri- or postoperatively (data not 
shown). 
  
 
3.2.4 Heart function 
Left ventricular contractility was measured by transthoracic echocardiography before and 
4 weeks after cryoinjury or sham operation. No differences in shortening fraction were found 
between groups before surgery. At the end of the observation period, LV contractility in the 
control group was significantly reduced in comparison with sham operated animals (41.3±0.8% 
vs. 46.2±1%, p=0.01) (Figure 3.10). Injection of human UCBCD133 cells in the cryolesion had no 
beneficial effect on shortening fraction (SF=40.8±0.7%, p=0.7 vs. control). In contrast, treatment 
with human BMCD133 cells almost completely prevented the decrease of contractility 
(SF=45.4±0.9%, p=0.02 vs. control). In order to evaluate heart function under stress conditions, 
anaesthetized mice were treated with dobutamine (200 µg/kg, s.c.). Dobutamine produced a 
similar increase in heart rate in all groups (from 405±8 to 543±8 beats per minute). Contractility 
also markedly increased in all groups, however, the relative increase was more pronounced in 
sham operated mice (18.0±1.5%) than in the cryoinjury groups (10.5±1.6%, p=0.02 vs. sham). 
Under dobutamine stress, shortening fraction in BMCD133 cell treated mice remained significantly 
higher than in control mice or UCBCD133 treated hearts.  
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Figure 3.10 Left ventricular shortening 
fraction as a measure of myocardial 
contractility measured 28 days 
postoperatively by transthoracic 
echocardiography, both at rest ("baseline") 
and under catecholamine stress provoked 
by injection of dobutamine 
("dobutamine"). Compared with sham-
operated animals, cryoinjury led to a 
significant reduction in shortening fraction 
("control"). Injection of UCBCD133 cells 
had no measurable effect on contractility, 
but BMCD133 cells completely prevented or 
reversed to loss of contractile function at 
rest, and partially under dobutamine stress. 
*p<0.05 vs. sham group, #p<0.05 vs. 
control group. 
  
 
3.2.5 Heart morphology 
Histological analysis demonstrated that cryoinjury consistently produced transmural myocardial 
necrosis (Figure 3.11). In the injured region profound scar formation and wall thinning was 
observed after 28 days. The size of scar area did not significantly differ between BMCD133 cell-
treated, UCBCD133 cell-treated, and control animals (Figure 3.12A). There was also a significant 
increase in heart weight-to-body weight ratio in all cryoinjured mice, again without relevant 
differences between the treatment groups (Figure 3.12B). The development of LV dilatation and 
partial compensatory hypertrophy was also mirrored by increased left ventricular end-diastolic 
dimensions on echocardiography (data not shown). Again, there was no measurable effect of 
BMCD133 or UCBCD133 cell transplantation.  
3.2.6 Identification of transplanted cells 
Forty-eight hours after transplantation, human cells could readily be detected by immunostaining 
using human specific antibodies (hNuc or HLA-1) in both BMCD133 and UCBCD133 transplanted 
hearts (Figure 3.13A). There was no evidence of transplanted human BMCD133 or UCBCD133 cells 
that co-expressed myosin heavy chain. One month after cell transplantation, neither BMCD133 nor 
UCBCD133 derived hNuc+ or HLA-1+ human cells could be visualized in any of the sections 
studied by immunofluorescence. However, human DNA was clearly present in all cell-treated 
hearts and was identified by PCR using a human specific primer (Figure 3.13B and C). 
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Figure 3.11 (A) Gross 
morphology following Sirius 
red staining of a normal left 
ventricle (transverse section) 
in the sham operation group, 
and (B) a heart 4 weeks after 
cryoinjury (control group) 
without cell injection. (C) 
4 weeks after cryoinjury and 
injection of UCBCD133 cells, 
and (D) after injection of 
BMCD133 cells. 
 
 
Figure 3.12 (A) Scar size after 4 weeks 
in hearts of sham operated animals 
("sham") and mice that underwent 
cryoinjury alone ("control") or with 
injection of BMCD133 or UCBCD133 cells. 
Scar size was measured by 
computerized planimetry on Sirius Red 
stained sections from mid-level of the 
lesion. There was no difference between 
control and cell-treated hearts. (B) Heart 
weight-to-body weight (HW/BW) ratio 
in %. Mice with cryoinjury had a higher 
HW/BW ratio, indicating some degree 
of compensatory hypertrophy of the 
remaining viable myocardium. Cell 
injection had no effect on this 
parameter. 
 
 
3.2.7 Capillary density 
Capillary density in the border zone of the cryolesion was determined based on CD31 
immunostainingOverall, capillary density in cell-treated hearts was approximately 25% higher 
than in control hearts with a cryolesion. (Figure 3.14), whereas there was no significant difference 
in capillary density between BMCD133 and UCBCD133 cell-treated hearts (control, 10.7±0.7 
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vessels/HPF; BMCD133, 13.3±2.3 vessels/HPF, p=0.04 vs. control; UCBCD133, 14.3±2.6 
vessels/HPF, p=0.005 vs. control, p=0.2 vs. BMCD133).  
 
 
 
 
 
Figure 3.13 (A) Detection of 
human cells 48 h after cryoinjury 
and BMCD133 cell injection by 
immunostaining for human 
nuclear antigen (hNuc) and 
counterstaining of all nuclei with 
DAPI (original magnification 200 
x). Both BMCD133 and UCBCD133 
cells could readily be detected 
48 h after injection. After 
4 weeks, however, hNuc staining 
was negative in all examined 
sections. (B, C) Detection of 
human DNA 4 weeks after 
cryoinury and cell injection by 
PCR using the human-specific 
primers D7A and D7B of α- 
satellite of chromosome 7 Locus 
D7Z1. All examined hearts that 
had been treated with BMCD133 (B) 
or UCBCD133 (C) cell injection 
were PCR-positive. 
MW=molecular weight marker 
 
 
Figure 3.14 Blood vessel density in the border zone of the cryolesion 4 weeks postoperatively.Average blood vessel 
count per high power field counted in 10 randomly chosen high-power fields (HPFs) in 2 sections per heart and 6 
hearts per group. In cell-treated hearts, blood vessel density was approximately 25% higher than in control hearts. 
*p<0.05 vs. control. 
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3.2.8 Tunel assay 
Numerous Tunel-positive nuclei were identified in the area of the cryolesion 24 h postoperatively 
(Figure 3.15). In general, they also showed condensed nuclei as another typical feature of 
apoptosis. In control animals, the apoptotic nuclei count was approximately 5-fold higher in the 
center of the cryolesion than in remote normal myocardium, and 12-fold higher in the necrosis 
border zone. Compared with BMCD133 or UCBCD133 cell-treated hearts, there was no difference in 
TUNEL-positive nuclei count in the center of the cryolesion (Figure 3.15B). However, injection 
of BMCD133 cells resulted in a significant reduction of cardiomyocyte apoptosis in the border zone 
(3.9±1.6% vs. 7.5±1.3% in control, p=0.02). In the border zone of UCBCD133 cell-treated hearts, 
apoptosis seemed to be reduced to a similar degree, but the difference did not reach statistical 
significance (4.3±0.7%, p=0.14 vs. control). In the remote normal myocardium as well as in the 
center of the cryolesion, the percentage of TUNEL-positive cardiomyocytes was not significantly 
different between the groups.  
 
 
 
Figure 3.15 Apoptosis in the myocardium 
following cryoinjury with or without cell 
injection. (A) TUNEL staining with DAPI 
counterstaining of all nuclei, depicting 
several TUNEL+ nuclei and one TUNEL+ 
capillary (arrow). (B) Detail magnification 
of a TUNEL+ nucleus embedded between 
or within myofibrils. (C) The same image 
merged with DAPI stain. The TUNEL+ 
nucleus appears to be part of a 
multinucleated myofiber, however, it can 
not be clearly distinguished from an 
interstitial cell. 
3.2.9 Discussion 
Although the notion of cardiomyocyte-differentiation of unmodified adult stem cells appears to 
be unrealistic at present [149], a variety of experimental studies in small and large animals have 
indicated that haematopoietic stem cells and/or endothelial progenitor cells can improve heart 
function upon delivery to diseased myocardium. While basic researchers have identified very 
promising adult stem cell types utilizing complex ex vivo cell isolation and manipulation 
strategies [150][151][152], clinicians are currently limited to using clinically available cell 
products. In this context, the CD133 antigen has attracted interest because it is expressed on the 
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surface of endothelial progenitor cells and presumably also on cells with a particularly high 
degree of stemness (i.e. CD133+/CD34 – cells), and because protocols for large-scale isolation by 
immunomagnetic selection of native cells are readily available. Following the advent of clincial 
trials using CD133+ bone marrow or blood-derived cells, Agbulut et al. first demonstrated the 
functional efficacy of human CD133+ marrow cells in an immunodeficient rat model of ischemic 
myocardial infarction [153]. Similar to their observation, we were not able to detect transplanted 
BMCD133 cells by immunofluorescence several weeks after implantation, although the persistence 
of their progeny in the heart was evidenced by PCR. The reasons for the disappearance of 
histologically detectable cells are not clear. The immunodeficient NOD/SCID mouse model has 
been extensively used in xenogenic cell transplantation studies [154], but some residual 
immunologic host activity against the xenogenic cell graft cannot be completely excluded. 
Alternatively, pharmacologic immunosuppression might be used, but this could also interfere with 
cellular proliferation and differentiation. It is not clear, either, why hDNA can be detected by 
PCR in the absence of positive immunostating for human cells. Possible, albeit largely 
speculative, explanations are fusion of transplanted human cells with host cells [155][156], 
persistence of hDNA following phagocytosis or lysis of graft cells, or simply the different levels 
of sensitivity of both detection methods.  
Although the echocardiographic assessment of LV contractility in mice may be less accurate than 
intracardiac recording of pressure–volume loops in rats (as was done by Agbulut et al. [153]), our 
data confirm the functional benefit derived from BMCD133 cells. The possible reasons for this 
increase in contractile function are manifold, but, admittedly, the results of our experiments are 
not sufficiently conclusive to point out one specific mechanism-of-action. Along with many other 
groups, we did not find convincing evidence of cardiomyocyte-like differentiation of BMCD133 
cells, but our in vitro experimental approach was certainly limited. It should not be ruled out that 
some myocyte differentiation potential of human hematopoietic/endothelial progenitor cells does 
exist, provided there is direct contact with host cardiomyocytes, as has been indicated in several 
in vitro co-culture or in vivo studies [157]. Nevertheless, we did detect a significant impact on 
vascularization of the injured myocardium [158], and found that the presence of BMCD133 cells 
appears to reduce the number of apoptotic cells in the infarct border zone, although this 
phenomenon did not result in a measurable difference in infarct size. In fact, we did not expect to 
see a relevant impact on the size of the necrosis area, since the cryolesion instantly produces an 
irreversible transmural necrosis that could only be expected to decrease in size when substantial 
neo-myogenesis would occur. The most solid albeit least specific line of evidence, however, is 
the beneficial impact on post-injury mortality. Whatever the mechanism may be, some benefit of 
CD133+ cells in the heart does exist.  
CHAPTER 3                                                                                          STEM CELL FOR CARDIAC REPAIR                         
 44 
In the typical clinical target population, older patients with advanced ischemic heart disease, the 
regenerative capacity of autologous adult stem cells is probably reduced [159], and cord blood-
derived cells have been suggested as an attractive alternative with enhanced angiogenic and 
hematopoietic potential [160-164]. In a previous study, we have shown that human cord blood 
mononuclear cells injected intravenously migrate to the ischemic mouse heart and facilitate 
angiogenesis processes [165]. Similarly, Leor et al. described beneficial functional effects of 
CD133+ cord blood cells after intravenous infusion in athymic rats with myocardial infarction 
[166], and Yang et al. reported on the angiogenic capacity of expanded UCBCD133 in ischemic 
hind limbs [167]. We therefore decided to directly compare the efficacy of BMCD133 and UCBCD133 
cells in the present study, and found a similar effect on post-injury survival and blood vessel 
density. In vitro, both BMCD133 and UCBCD133 cells were able to form capillary-like structures and 
to differentiate into endothelial cells and/or their immediate progenitors. Besides primary 
endothelial differentiation of CD133+ cells, the increase in blood vessel density in vivo might 
also be attributed to the generation of angiogenic growth factors. In this context, Pomyje et al. 
demonstrated the expression of angiopoietin-1, angiopoietin-2 and vascular growth factor as well 
as their receptor mRNAs in CD34+/CD133+ human UCB cells in vitro, supporting the notion of 
a paracrine action of these cells in the regulation of angiogenesis [168]. The increase in blood 
vessel density most likely increases local blood flow in the necrosis border zone, thus delaying or 
preventing the onset of apoptosis. Alternatively, direct anti-apoptotic actions due to secreted 
cytokines or other graft-host cell interactions may also play a role.  
On the other hand, there was no measurable impact of UCBCD133 cells on LV contractility, and the 
reduction of apoptosis did not reach statistical significance. Taken together, UCBCD133 cells 
appear to less potent than BMCD133 cells in preventing or reversing myocardial injury, at least in 
the model used here, although in vitro they appear to be similarly potent endothelial progenitor 
cells. In an attempt to find an explanation for this counterintuitive finding, we compared the 
expression profile of a number of "stemness"-related surface markers. The only difference we 
found is an approximately 50% lower percentage of CD117+ cells among UCBCD133 cells. The 
proto-oncogene c-KIT/stem cell factor receptor/CD117 is thought to modulate cellular 
differentiation and proliferation processes but also to inhibit apoptosis, and one might assume that 
less CD117+ cells in a given cell product indicate an overall lower functional capacity [169]. 
However, our study is only observational and does not provide data to prove this notion. There is 
a multitude of other confounding factors that might also help explain the differences between 
BMCD133 and UCBCD133 cells, including the UCB preservation protocol and possibly a higher 
content of mesenchymal-type stem cells in BM-derived cell products.  
In summary, we found that CD133+ cells from human bone marrow clearly have beneficial 
effects on the hearts subjected to an extensive cryolesion, improving survival, contractility and 
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vascularization, and inhibiting myocardial apoptosis. The experimental support for the ongoing 
clinical pilot trials using similar cell products therefore seems to grow. The corresponding cell 
product derived from cord blood appears to be less potent, and further studies are required to 
elucidate the reasons for this discrepancy. 
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Chapter 4  Genetic Manipulation towards Better Stem Cell Survival (Publication E) 
4.1 Introduction 
Considerable experimental and clinical evidences have demonstrated that using different cell 
types to replace the necrotic tissue in the myocardium is safe and can contribute to the 
improvement of angiogenesis and heart functions [170-175]. Among the various cell types 
investigated, bone marrow MSCs are self-renewing clonal precursors of non-hematopoietic 
stromal tissues [176]. They can be isolated from the bone marrow or adipose tissue and expanded 
in culture based on their ability to adhere to culture dishes and proliferate in vitro. MSCs are 
multilineage potential cells [177] and can give rise to osteoblasts, chondrocytes [178], neurons 
[179], skeletal muscle [180] and cardiac muscle [181][182] under appropriate conditions. 
Furthermore, studies on human, baboon and murine MSCs showed that MSCs are 
immunosuppressive [183][184]. Therefore, MSCs appear to be an appealing cell source for 
cardiac transplantation [171][185] because of the ease of harvest and expansion ex vivo. 
However, the low cellular survival rate after transplantation into an infarcted heart within the first 
few days engenders only marginal functional improvement [182][186]. Thus, it is necessary to 
reinforce MSCs against the arduous microenvironment incurred from ischemia, inflammatory 
response and pro-apoptotic factors in order to improve the efficacy of cell therapy. 
 
The 26-kDa Bcl-2 anti-apoptotic protein belongs to the Bcl-2 family of proteins, which was 
originally found to be overexpressed in B-cell lymphoma. It serves as a critical regulator of 
pathways involved in apoptosis, acting to inhibit cell death. Bcl-2 gene was found to be up-
regulated in failing hearts [187][188] as well as aging hearts [189]. It acts to prevent programmed 
cell death of ventricular myocytes [190].The protective effects of Bcl-2 for conditions of the 
diseased heart have been approved by previous studies [190][191]. Interestingly, overexpressing 
Bcl-2 in transgenic mice improved the heart function and inhibited cardiomyocyte apoptosis.  
 
In this study, adult rat bone marrow-derived MSCs were genetically modified to overexpress Bcl-
2, which aimed at vivifying the stem cells and enhancing their resistance to ischemic conditions 
from acute myocardial infarction after transplantation into the heart. We proposed that genetic 
modification of stem cells with Bcl-2 would armour stem cells settling into a deteriorative 
ischemic microenvironment, improve stem cell viability in the early post-transplanted period and 
thereby enhancing cardiac functional recovery after acute myocardial infarction. 
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4.2 MSCs express markers distinct from hematopoietic stem cells 
Cell isolation, expansion, characterization and differentiation of rat MSCs have been established 
according to previous reports [177]. The morphology of rat MSCs from bone marrow displayed a 
homogenous spindle-shaped population and maintained a similar morphology during the 
subsequent passages. FACS analysis was employed to identify the surface marker expression. 
The MSCs culture was shown to be devoid of CD34 and CD45 (Figure 4.1D and E), which are 
the markers for hematopoietic cells. In contrast, a high expression of CD29, CD44, CD90 
markers were observed (Figure 4.1A, B and C).  
 
 
 
Figure 4.1 Immunophenotypic profile of MSCs. Flow cytometry histograms after three passages show the 
expression (unshaded) of selected surface molecules; (A): CD29; (B): CD44; (C): CD90; (D): CD34; and (E): 
CD45. Control cells labeled without primary antibodies (shaded). The rat MSCs were positive for CD29, CD44, 
and CD90 but negative for CD34 and CD45 surface markers, which are commonly found on hematopoietic cells. 
 
4.3 Overexpression of Bcl-2 in genetically modified MSCs 
The transfection efficiency of Polyethylenimine for genetic modified MSCs was evaluated by 
pcDNA3.1/GFP as an internal control after 24 h gene delivery. More than 50% of MSCs were 
transfected based on FACS analysis (Figure 4.2B). To evaluate the expression of Bcl-2 protein in 
the genetically modified MSCs in vitro, Western blot analysis was performed on cell samples at 
various time points (24 h, 72 h, 7 days and 21 days) post-transfection. A significantly high 
expression of Bcl-2 was observed in Bcl-2-MSCs as early as 24 h, which remained detectable on 
day 7 (Figure 4.2C). In contrast, a weak expression of Bcl-2 was detected in vector-MSCs 24 h 
after transfection, indicating the low level of endogenous Bcl-2 proteins in MSCs. The expression 
of internal housekeeping β-actin gene was at the same level. Our observation showed that the 
MSCs were successfully modified with Bcl-2. The up-regulation of Bcl-2 was transient and this 
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may minimize the risk of malignant transformation or late cell failure. No apparent change of 
MSCs phenotype after transfection was observed (data not shown). 
 
 
Figure 4.2 Transfection of MSCs with nonviral vector. (A): Representative photomicrograph of MSCs 
transfected with pcDNA3.1/GFP. (B): Fluorescence-activated cell sorter analysis showing the transfection 
efficiency of GFP transfected MSCs (unshaded) compared with untransfected MSCs (shaded). (C): 
Representative Western blots showing that Bcl-2 was overexpressed in Bcl-2 modified MSCs and lasted for 7 
days after transfection. Housekeeping protein ß-actin served as loading control. Abbreviations: d, days; GFP, 
green fluorescent protein; h, hours. 
 
 
4.4 Bcl-2 modified MSCs maintain their multi-differentiation capacity 
MSCs can differentiate into multi-lineages (such as bone, cartilage, adipose tissue and cardiac 
muscle) and this ability is taken as a functional criterion defining MSCs precursor cells. To verify 
if the Bcl-2 modification affected the differentiation capacity, the genetically modified MSCs 
underwent myogenic, adipogenic and chondrogenic differentiation using the methods previously 
described [181][192] at 48 h post-transfection. After 21 days of induction towards an adipogenic 
lineage, a characteristic morphological change with accumulation of lipid vacuoles was observed 
(Figure 4.3A). Immunostaining revealed the presence of fatty acid binding protein-4 (FABP-4), 
which is a marker protein for adipocytes. Chondrogenesis was assessed by immunostaining for 
aggrecan after 4 weeks of culture under chondrogenic conditions. The chondrocyte-like cells 
showed positive staining for aggrecan protein (Figure 4.3B, C and D). For cardiomyocyte 
differentiation, Bcl-2-MSCs were exposed to 5-azacytidine for 24 h. After two weeks, 
cardiomyocyte-like cells and positive immunostaining for Nkx2.5 were noted (Figure 4.3E, F, 
and G). Taken together, this evidence indicated that Bcl-2-MSCs retain their multi-differentiation 
potential into adipogenic, chondrogenic and cardiomyocyte lineages.  
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Figure 4.3 Differentiation capacity of Bcl-
2-MSCs. MSCs transfected with Bcl-2 
were cultured in adipogenic, 
chondrogenic, and myogenic medium for 
up to 2 months. (A): Adipogenic 
differentiation. Immunostaining with fatty 
acid binding protein-4 (brown). (B–D): 
Chondrogenic differentiation. 
Immunostaining for aggrecan ([B, D], 
red). Nuclei were counterstained with 4,6-
diamidino-2-phenylindole ([C, D], blue). 
(E–G): Cardiomyocyte-like 
differentiation. Immunostaining with anti-
Nkx2.5 antibody ([E, G], green). Nuclei 
were counterstained with propidium 
iodide ([F, G], red). 
 
 
4.5 Bcl-2 modified MSCs protect against apoptosis in vitro 
To test the capability of Bcl-2-MSCs to protect against apoptosis in vitro, the modified MSCs 
were treated under hypoxic conditions for 24 h. The evaluation of apoptosis was carried out using 
TUNEL assay (Figure 4.4A) and Hoescht 33342 staining (Figure 4.4B). Under hypoxia, the rates 
of cell apoptosis in MSCs and vector-MSCs exceeded those of Bcl-2-MSCs by 1.5 fold. The 
apoptotic cell number was significantly reduced by the Bcl-2 genetic modification. Quantitative 
assay showed that the number of TUNEL-positive cells was decreased from 53±3.5% of MSCs 
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and 51±4.7% of vector-MSCs to 36%±1.8% (n=6, p<0.001) of Bcl-2-MSCs. However, there was 
no significant difference in apoptotic cell numbers between MSCs, vector-MSCs and Bcl-2-
MSCs when evaluated under normoxia. A further confirmatory assay was based on nuclear 
chromatin morphology after staining with Hoescht 33342. Apoptosis was evidenced by cell 
shrinkage; nuclear condensation and DNA fragmentation that occurred in cells treated with 
hypoxia (Figure 4.4B). The quantitative assay based on Hoescht staining showed that the number 
of apoptotic cells was decreased from 46±3.1% of MSCs and 45±4.2% of vector-MSCs to 
30±2.6% of Bcl-2-MSCs (n=6, p<0.001). These findings demonstrated that the Bcl-2 modified 
MSCs could protect against apoptosis under hypoxic conditions. It is anticipated that Bcl-2 
modified MSCs may retain their anti-apoptotic properties in the ischemic myocardium.  
 
 
 
 
Figure 4.4 Antiapoptotic effect and upregulation of VEGF secretion of Bcl-2-MSCs under hypoxic conditions. 
(A): Representative photomicrographs of TUNEL-positive (left panels) and total (right panels) cells after 24 
hours of hypoxic treatment. (B): Representative photomicrographs of apoptotic cells (arrows) with chromatin 
condensation by Hoechst 33342 staining after 24 hours of hypoxic treatment. (C): VEGF secretion by Bcl-2-
MSCs under hypoxic conditions. After 24 hours of incubation, conditioned medium from normoxia (solid bar) 
and hypoxia (empty bar) treated cells (n = 6) was subjected to VEGF enzyme-linked immunosorbent assay 
(ELISA) assay. VEGF concentration values are mean ± SD (* p < .001). ELISA data are representative of three 
independent experiments. Abbreviations: PI, propidium iodide; TUNEL, terminal deoxynucleotidyl transferase-
mediated dUTP end labeling; VEGF, vascular endothelial growth factor. 
 
4.6 Bcl-2 modified MSCs upregulated angiogenic cytokine VEGF under hypoxia 
To identify potential paracrine mechanisms responsible for the therapeutic effect of Bcl-2-MSCs, 
we examined the secretion of VEGF. MSCs, vector-MSCs and Bcl-2-MSCs were cultured under 
either normoxic or hypoxic conditions for up to 24 hours and VEGF secretion was quantitated by 
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Quantikine rat VEGF immunoassay. A more than 60% increase in secretion of VEGF was 
detected in Bcl-2-MSCs compared to MSCs alone and vector-MSCs when the cells were cultured 
under hypoxic conditions (Figure 4.4C). However, there was no significant difference among the 
groups when the cells were cultured under normoxic conditions. The angiogenic cytokine VEGF 
was significantly up-regulated in Bcl-2-MSCs in response to hypoxic conditions. The high level 
expression of VEGF from Bcl-2-MSCs may provide cardioprotective and pro-angiogenic effects. 
4.7  Cell engraftment with Bcl-2 modified MSCs in the infarcted heart 
To assess the efficacy of Bcl-2-MSCs transplantation, 6×106 Bcl-2-MSCs or vector-MSCs from 
passage 3 were transplanted into the viable (Left Ventricle)LV myocardium bordering infarction. 
Medium was injected into control animals. The assessment of cell engraftment was carried out 4 
days, 3 weeks and 6 weeks after cell transplantation. BrdU positive nuclei were identified by 
immunostaining (Figure 4.5A-E). Figure 4.5A and B depicted representative images 4 days 
following cell transplantation. Figure 4.5C-E showed representative images of Bcl-2-MSCs cells 
in the heart of a MI+ rat sacrificed 3 weeks after cell injection. The number of surviving cells in 
Bcl-2-MSCs group was greater than in vector-MSCs following cell transplantation and the 
differences proved to be statistically significant, with 2.2-fold enhancement of cell survival on 
day 4 (n=10, p<0.01), 1.9-fold enhancement on day 21 (n=9, p<0.05) and 1.2-fold enhancement 
after 6 weeks (n=6, p<0.05). Manipulation MSCs with Bcl-2 gene enhanced cellular survival 
after myocardial infarction. 
Furthermore, double immunofluorescence staining with BrdU and anti-vWF antibody revealed 
that at least some of the MSCs cells (3.1±1.3%) appeared to display endothelial cell-like 
phenotype. Occasionally, blood vessels consisted of BrdU positive cells (Figure 4.6A and B). 3 
weeks after cell transplantation, we observed a very few number of MSCs colocalized with 
cardiac Troponin T (cTnT) (Figure 4.6C-E). The colocalization was further confirmed by the 3-D 
reconstruction of the tissue acquired by a Leica TCP2 confocal microscopy (Figure 4.6F -H). The 
frequency of cTnT –BrdU double positive cells from the engrafted stem cells was extremely low 
(Bcl-2-MSCs group 0.05±0.02% cTnT). There was no significant difference between Bcl-2-
MSCs and MSCs group. It was not clear whether the transplanted cells had fused or differentiated 
into cardiomyocytes. There is no evidence for tumor formation and MSCs differentiation into 
bone, adipose and cartilage after 3 and 6 weeks cell transplantation (data not shown).  
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Figure 4.5 Engraftment of Bcl-2-MSCs in ischemic myocardium. (A, B): Representative images from 
immunostaining of grafted MSCs in the infarcted rat myocardium 4 days following MSC injection. BrdU-labeled 
MSCs (brown) were clearly identified. (C–E): Immunofluorescence staining of BrdU-labeled cells in the Bcl-2-
MSC group 3 weeks after cell treatment with high magnification. (C): BrdU (red). (D): DAPI (blue). (E): 
Merged image (×1,000 in all panels). Arrowheads indicate the cell engraftments.  
4.8 Capillary density 
Capillary density at the border zone of the acute myocardial infarction (AMI) was determined 
based on vWF immunostaining 3 weeks after cell transplantation. There was a significant 
increase in capillary density in vector-MSCs (20.5±1.9 vessels/HPF) and Bcl-2-MSCs (23.6±1.3 
vessels/HPF) groups when compared with medium-treated hearts with AMI (14.4±2.1 
vessels/HPF) (n=8, p<0.001) and no obvious angiogenesis was detected in the medium group. In 
addition, the capillary density was 15% higher in Bcl-2-MSCs treated hearts than in vector-MSCs 
treated hearts with significant difference (n=8, p=0.002). 
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Figure 4.6 Bcl-2-MSCs in ischemic myocardium. (A, B): Double immunofluorescence staining revealed BrdU-
labeled Bcl-2-MSCs (green) incorporated into the endothelial lining of blood vessels (red) near the infarct border 
zone 3 weeks after transplantation. (C–E): Three weeks after transplantation, sections near the infarct zone were 
double-stained for BrdU (green) and cardiac marker Troponin T (red). BrdU-positive cell colocalized with cardiac 
Troponin T. (F–H): Three-dimensional reconstruction of the tissue section using confocal microscopy illustrates 
that BrdU-positive nucleus (green) is within a cell body that expresses cardiac Troponin T. Cardiac-like cells were 
stained for Troponin T; BrdU-positive cells were identified (primary antibody: monoclonal mouse anti-BrdU 
antibody; secondary antibody: Alexa 488).. 
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4.9 Infarct size and cardiac function 
LAD ligation consistently resulted in transmural myocardial infarction, exhibiting typical 
histologic changes including thinning of the left ventricular free wall and extensive collagen 
deposition 3 weeks after myocardial infarction. Both vector-MSCs treated and Bcl-2-MSCs 
treated MI+ animals showed smaller infarction size (34.2±6.0% in vector-MSCs group; 
28.3± 5.8% in Bcl-2-MSCs group) compared with the medium treated animals (47.8±6.3%) and 
the difference was statistically significant (n=8, p<0.001 vector-MSCs group vs. medium group; 
n=8, p<0.001 Bcl-2-MSCs vs. medium group). Further, the collagen content was 17% lower in 
Bcl-2-MSCs treated hearts than in vector-MSCs treated hearts (34.2±6.0% of vector-MSCs group 
vs. 28.3± 5.8% of Bcl-2-MSCs group) (n=8, p=0.029). 
 
Hemodynamic parameters of left ventricular function demonstrated that max dP/dt and min dP/dt 
were improved significantly in Bcl-2-MSCs group than in vector-MSCs group (n=6, p<0.001). 
Compared with medium group, both Bcl-2-MSCs and vector-MSCs group had significant 
improvements on hemodynamic parameters such as end-systolic volume (ESV), ejection fraction 
(EF) , Maxium dP/dt and Minimum dP/dt. Furthermore, there were significant improvements in 
Bcl-2-MSCs group on end-diastolic volume (EDV), end-systolic pressure-volume relationship 
(ESPVR) and Emax compared to medium group (Bcl-2-MSCs group: 239.2±35.9 µl of EDV, 
0.58±0.14 mmHg/µl of slope ESPVR, 1.50±0.34 mmHg/µl of Emax vs. medium group: 
292.1±39.0 µl of EDV, 0.36±0.16 mmHg/µl of slope ESPVR, 0.93±0.39 mmHg/µl of Emax) 
(n=6, p<0.05). However, there was only a positive trend toward improvement on EDV, ESPVR 
and Emax between vector-MSCs group and medium group, and the difference did not reach 
statistical significance. No significant difference was observed on the values of V0 between Bcl-
2-MSCs group (83.4±14.1 µl) and vector-MSCs group (79.4±13.0 µl), or between Bcl-2-MSCs 
group and the medium group (87.2±15.8 µl). 
 
4.10 Discussion 
MSCs derived from adult bone marrow have been proposed as a promising cell source for the 
regeneration and restoration of infarcted heart function. However, poor survival of implanted 
cells hampered the therapeutic efficacy. In this study, the key roles of Bcl-2 played in protecting 
grafted MSCs survival under hypoxia-ischemia were identified in vitro and in vivo. We 
confirmed that Bcl-2 genetically modified MSCs retained their differentiation capacity and could 
give rise to different lineages in vitro. Overexpression of Bcl-2 reduces MSCs death and 
apoptosis under hypoxic conditions. In vivo transplantation of Bcl-2-MSCs enhances the survival 
rate of MSCs in the LAD ligation model. It could attenuate post infarction left ventricular (LV) 
remodelling and restore LV function, which may have attributed to the enhanced anti-apoptotic 
properties of the modified MSCs. These observations suggest that genetic modification of MSCs 
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with Bcl-2 could be of significant value in improving the efficacy of stem cell therapy following 
a broad range of cardiac diseases. Our results agree with the earlier findings that transgenic mice 
over-expressing Bcl-2 in the heart reduced infarct size and improved recovery of cardiac function 
after ischemia/reperfusion injury [191][193][194].  
 
There are several mechanisms contributing to the high level of stem cell death within 4 days after 
implantation into ischemic hearts [182][186]. These include host inflammatory response, loss of 
survival signal from matrix attachments or cell-cell contact, delivery of oxygen and substrates via 
diffusion [182][186], various pro-apoptotic or cytotoxic factors in the ischemic [195] and 
ischemic/reperfusion damage to the implanted stem cells incurred from repeated bouts of 
ischemia [196]. Furthermore, MSCs are extremely sensitive to the hypoxic and inflammatory 
environment in ischemic hearts [182]. Our present studies revealed that genetic modification of 
MSCs with Bcl-2 effectively protects transplanted MSCs against ischemia and increases cell 
survival after implantation. Our investigation, consistent with previous findings from Mangi et al. 
[176] and Tang et al. [196], showed that the therapeutic efficacy of MSCs was closely related to 
the in situ survival of cells implanted in the hostile environment of hypoxia, inflammation and 
scarring from myocardial infarction. Hence, the survival essential factors for the MSCs, such as 
cytokines, chemokines, integrins and other adhesion molecules need to be further addressed 
quantitatively.  
 
It was recently reported that persistent overexpression of VEGF in nonischemic myocardium may 
cause the formation of vascular tumors [197]. The present study for the first time, demonstrated 
the high level expression of VEGF from Bcl-2-MSCs in response to the hypoxic conditions. 
Therefore, transplantation of Bcl-2-MSCs could provide adequate magnitude and duration of 
VEGF expression in the ischemic myocardium without formation of vascular tumors. The high 
level expression of VEGF from Bcl-2-MSCs transplanted to the ischemia-damaged myocardium 
would provide cardioprotective effects and induce functional collateral vessels which contribute 
to the salvaging of ischemic myocardium and decrease the infarct area. 
 
However, it is still not clear whether intramyocardially transplanted MSCs function as newly 
differentiated cardiomyocytes and endothelial cells or serve as the paracrine cells by secretion of 
cardioprotective proteins. Our study and those of other groups [196][198][199] confirmed that 
grafted implanted MSCs can secrete important survival factors, including VEGF, insulin-like 
growth factor, hepatocyte growth factor, SDF-1 and basic fibroblast growth factor. Considering 
the low frequency of new cardiomyocytes and endothelial cells [196][200], this paracrine effect 
could be even more important for the functional recovery of the infarcted heart than the 
transdifferentiation potential of stem cells. Therefore, a quantitative assay of the paracrine 
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cytoprotective factors from stem cells cocultured with cardiomyocytes subjected to hypoxia 
deserves significant attention. The cocktail of paracrine cytoprotective factors may bring fresh 
therapeutic options to a number of diseases, including heart failure. 
 
Our current work, together with many other studies demonstrated that bone marrow MSCs 
implantation could induce therapeutic angiogenesis in infarcted heart [201-204] or ischemic 
tissue [205]. Our data suggested that the viability of transplanted cells is one of the important 
factors for preservation of myocardial function and the therapeutic angiogenesis is not linearly 
correlated with the survival rate of the transplanted cells. The underlying mechanism of 
angiogenesis is very complicated. For instance, MSCs are able to differentiate into vascular 
endothelial cells in the ischemic myocardium and generate capillary like structure 
[201][202][204]. Meanwhile, MSCs enhance angiogenesis partly by increasing endogenous 
levels of vascular endothelial growth factor and vascular endothelial growth factor type 2 
receptor [205]. Our evidence support the theory that the paracrine effect of MSCs might be one 
of the major reasons for therapeutic angiogenesis. Using genetic modification approach may 
further enhance the cytoprotective effect and restore MSCs angiogenesis effect.  
 
In the present study, a significant increase in nucleosomal DNA fragmentation and DNA 
condensation by TUNEL and Hoechst 33342 nuclear staining was observed in MSCs subjected to 
hypoxic conditions compared with the normoxic control cells, a finding concordant with previous 
data verifying that hypoxia provokes apoptosis of MSCs [176]. It is known that hypoxia can 
induce Bcl-2 down regulation through Nuclear Factor-kB (NF-kB) in endothelial cells [206] and 
myocytes [207]. We provide the first direct evidence that Bcl-2 upregulation from exogenous 
delivery activates a survival pathway that is sufficient to suppress hypoxia-induced apoptosis of 
MSCs. The underlying mechanism by which Bcl-2 protects MSCs under hypoxia is still 
unknown. We speculate that NF-kB might play a pivotal role in the cytoprotective effect of Bcl-2 
on MSCs under hypoxic conditions. Further studies need to be conducted in order to support the 
hypothesis. 
 
Our hemodynamic data are in consistent with previous reports which demonstrated cardiac 
functional improvement after MSCs transplantation [208][209]. We found that Bcl-2-MSCs 
transplantation further reduced EDV and significantly enhanced the systolic functional recovery 
determined by slope ESPVR and Emax. These beneficial effects of Bcl-2-MSCs may, in part, 
attribute to VEGF secretion in response to the hypoxic environment, angiogenesis and the 
improved cellular survival after pre-treatment with the anti-apoptotic Bcl-2 gene.  
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In this investigation, MSCs were genetically modified with Bcl-2 by a cationic polymer based 
vector with several unique advantages such as easy surface modification with well-defined 
structure and chemical properties [210], relatively low toxicity, high capability for carrying large 
therapeutic genes and lack of immune responses. More importantly, transient overexpression of 
Bcl-2 modified MSCs benefited from the non-viral gene delivery vector may minimize the 
potential risk of tumorigenesis while providing safe and sufficient protection for transplanted 
MSCs from short-term ischemic damage, which plays a critical role in transplanted stem cell 
death [182]. Further works on the long term persistence, function and phenotype of Bcl-2 
modified MSCs treated with non-viral vectors need to be determined to safely realize the full 
potential of MSCs for myocardial regeneration. 
4.11 Conclusion 
In summary, we have confirmed that genetic modification with anti-apoptotic Bcl-2 gene resulted 
in high-level VEGF expression in response to the hypoxic conditions. It enhanced the survival of 
engrafted MSCs in the heart after acute myocardial infarction. The transplantation of Bcl-2 
modified MSCs ameliorated LV remodeling and improved LV function. Genetically engineering 
cells by Bcl-2 using a non-viral vector could be an effective strategy for increasing cell survival 
after cell transplantation while minimizing the potential risk of tumorigenesis. Transplantation of 
gene-engineered MSCs may provide a novel and effective approach in the treatment of acute 
myocardial infarction. 
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Chapter 5  Summary 
Stem cell therapy holds great promise in the future treatment of cardiac disease such as acute 
myocardial infarction, congestive heart failure, and chronic ischemic heart disease. Accumulating 
clinical and experimental evidence suggested there is the possibility of regenerating damaged 
myocardium using adult stem cells, which have generated enthusiasm for therapeutic 
developments towards cardiac regeneration.   
Several different stem cells have been demonstrated to increase cardiac function when injected 
into infarcted hearts in experimental models. However, the underlying mechanism by which such 
structural and functional recoveries are achieved is still unclear. Although it has been confirmed 
that the endothelial progenitor cells have the capacity to form new vessels which may contribute 
to cardiac remodelling and functional improvement, it is still under debate that adult bone-
marrow-derived mesenchymal stem cells (MSCs) may differentiate into cardiac myocyte-like cell 
for the damaged myocardium.  
A major limitation to the efficacy of cell therapy is the poor viability of the transplanted cells. 
Indeed, the functional improvement from stem cell therapy has been quite modest. Mechanisms 
contributing to the high level of stem cell death after implantation into ischemic hearts include 
host inflammatory response, loss of survival signal from matrix attachments or cell-cell contact, 
delivery of oxygen and substrates via diffusion, various pro-apoptotic or cytotoxic factors in the 
ischemic and ischemic/reperfusion damage to the implanted stem cells incurred from repeated 
bouts of ischemia. Furthermore, stem cells are extremely sensitive to the hypoxic and 
inflammatory environment in ischemic hearts. Genetic modification of stem or progenitor cells 
may represent an important advancement in regenerative medicine. By combining gene with cell 
therapy, one may be able to enhance stem cell function and viability. Indeed, genetic modification 
can improve survival, metabolic characteristics, contractility, proliferative capacity, or 
differentiation of the stem cells. Furthermore, the cells may become a vehicle for gene therapy 
whose secreted gene products can exert paracrine or endocrine actions that may result in further 
therapeutic benefits. Our present studies revealed that genetic modification of MSCs with Bcl-2 
effectively protects transplanted MSCs against ischemia and increases cell survival after 
implantation. Our investigation, consistent with previous findings, showed that the therapeutic 
efficacy of MSCs was closely related to the in situ survival of cells implanted in the hostile 
environment of hypoxia, inflammation and scarring from myocardial infarction. Hence, the 
survival essential factors for the MSCs, such as cytokines, chemokines, integrins and other 
adhesion molecules need to be further addressed quantitatively. All these studies proved that an 
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ideal combination of cell and gene therapy might represent a future strategy for myocardial repair 
and regeneration.  
The field of stem cell research is still at its very preliminary stage. A clear understanding of the 
ideal approach in terms of choice of cell type, time, and method of delivery may take years of 
investigation. Continued development and application of genetic manipulation approaches in 
stem cells will undoubtedly lead to more efficient guidance and control of stem cell fate and 
improved stem cell function by promoting survival, migration, proliferation, differentiation or 
reprogramming of stem cells, which eventually leads to the success of cardiac regeneration. 
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